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Abbreviations 
 
 
B/A   before-after study 
CI   confidence interval 
MD   mean difference 
RCT   randomized controlled trials 
SMD   standardized mean difference 
 
 
LCPUFA  long-chain polyunsaturated fatty acid 
 
n-6 LCPUFAs: 
LA   linoleic acid (C18:2n-6) 
GLA   γ-linolenic acid (C18:3n-6) 
DHGLA  dihomo-γ-linolenic acid (C20:3n-6) 
AA   arachidonic acid (C20:4n-6) 
 
n-3 LCPUFAs: 
ALA   α-linolenic acid (C18:3n-3) 
EPA   eicosapentaenoic acid (C20:5n-3) 
DPA   docosapentaenoic acid (C22:5n-3) 
DHA   docosahexaenoic acid (C22:6n-3) 
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1. Introduction 
“...it is necessary, while formulating the problems of 
which in our further advance we are to find the 
solutions, to call into council the views of those of 
our predecessors who have declared any opinion on 
this subject, in order that we may profit by whatever 
is sound in their suggestions and avoid their errors.” 
 
          Aristotle, De Anima 
 
The volume of the medical literature has increased spectacularly over recent 
decades; over 2 million articles published yearly in more than 20,000 journals 
(Hemingway 2009). On top of this, researchers, therapists, healthcare managers and 
policy makers often have to deal with unclear or contradictory results. Traditional, 
narrative reviews have been a part of the medical literature for a long time. Although 
narrative reviews may be useful to receive a general overview on a topic; they are 
inadequate to answer specific clinical questions. Systematic reviews can fulfil this 
need, providing high quality and comprehensive summaries. The main differences 
between narrative reviews and systematic reviews are summarized in Table 1. 
Table 1: Differences between narrative and systematic reviews 
Feature Narrative reviews Systematic reviews (minimum criteria) 
Question May not clear and concise Clearly formulated 
Sources and search Non-specified, potentially biased Comprehensive sources and explicit search strategy 
Selection Non-specified, potentially biased Criterion-based, uniformly applied 
Quality of the studies Variable Rigorous critical appraisal 
Data synthesis Qualitative and subjective Qualitative or if possible, quantitative (meta-analysis) 
Inference Sometimes evidence-based, but 
more often based on personal 
opinions 
Evidence-based 
Adopted and modified from González-de Dios et al. 2005. 
 
The value of evidence can be ranked on the basis of the quality of the study, and it 
ranges from expert opinions to systematic reviews of randomized controlled trials 
(RCTs), which represent the highest level of evidence (Figure 1). The systematic 
review can be defined as “a review of the evidence on a clearly formulated question 
that uses systematic and explicit methods to identify, select and critically appraise 
relevant primary research, and to extract and analyse data from the studies that are 
included in the review” (Summerbell and Moore 2007). The primary goal of the 
systematic reviews is to summarize the current best evidence on a topic, as well as 
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to determine the gaps and limitations in evidence and identify priorities for future 
research.  
Figure 1: Hierarchy of evidence 
Abbreviations: SR, systematic review; RCTs, randomized controlled trials. 
Adopted and modified from Phillips et al. 2009. 
Meta-analysis is the use of statistical techniques in systematic reviews to combine 
and summarize the results of individual studies; thus to increase the statistical power 
of studies with small sample size and improve the precision of the estimation of the 
effect. The first meta-analysis was performed by the influential English 
mathematician, Karl Pearson in 1904 (Rosenthal and DiMatteo 2001), and the term 
“meta-analysis” was coined by a social scientist and modern statistician, Gene V. 
Glass in 1976 (Gregson et al. 2002). Thousands of systematic reviews and meta-
analyses have been published in recent years, and standards for reporting them 
have been developed (Moher et al. 1999, Liberati et al. 2009). 
 
1.1. The process of systematic review 
1.1.1. Defining the review question and developing criteria for including studies 
Developing a clear and focused question is the first and probably the most important 
step in writing systematic reviews. This question should include four parts, referred to 
as PICO question: patients, population or problem; intervention, independent 
 
High 
quality RCTs 
All or none 
case series 
SR of cohort studies 
Cohort studies; low quality RCTs 
Outcomes research; ecological studies 
SR of case-controlled studies 
Case-controlled studies 
Case series; poor quality cohort and case-controlled studies 
Expert opinion 
SR 
of RCTs 
higher levels 
of evidence 
lower levels 
of evidence 
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variable or exposure; comparison; and outcomes of interest or dependent variable 
(Stone 2002). These four components may define much of the eligibility criteria for 
selecting the studies; however, topic-specific criteria are often necessary, e.g. study 
design, minimum intervention period, or baseline nutritional status. Precise inclusion 
of the review question and selection criteria into the study protocol can help to 
minimise bias and to ensure that results are reproducible. 
 
1.1.2. Searching for studies 
Systematic searches should include multiple electronic databases; MEDLINE 
(Medical Literature Analysis and Retrieval System Online), EMBASE (Excerpta 
Medica), and Cochrane Library are the most frequently used databases. Depending 
on the review topic, there are many specialized databases which can also be used. 
Development of a search strategy is an interactive process, and it is usually built up 
in a number of test searches. In order to construct an effective combination of search 
terms, it is necessary to break down the review question into elements. Thereafter, 
these PICO elements with appropriate synonyms, abbreviations, related terms, 
variant spellings and common misspellings can be combined with Boolean operators 
(AND, OR, NOT). Handsearching the pertinent journals, searching the reference lists 
of the included studies; moreover, personal communications with experts in the field 
can also be proposed in order to identify all the relevant studies. 
 
1.1.3. Study selection 
The selection of studies is usually conducted in two stages: the initial step is to 
screen the titles and abstracts in order to identify the potentially relevant papers, and 
the following step is to screen the full text of these selected papers for detailed 
assessment against the inclusion criteria. When the information is insufficient to 
make decision about inclusion or exclusion, it can be helpful to contact the authors 
for more details. Flow diagram showing the number of included/excluded studies is a 
simple and useful way to document the study selection process, and the reasons for 
exclusion can also be reported. 
 
1.1.4. Data extraction and quality assessment 
Data extraction is the process for obtaining the necessary information about study 
characteristics and findings from the studies. Because each review is different, data 
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extraction requirements and data extraction forms vary across reviews. Data 
extraction is closely linked to quality assessment; they are often undertaken at the 
same time. Studies are usually carried out with different degrees of methodological 
deficiencies; therefore the assessment of quality can give indication of the robustness 
of evidence derived from the included studies. Many scoring systems can be used to 
assess the quality (Jüni et al. 1999); however, none of these systems are widely 
accepted. 
 
1.1.5. Data synthesis and meta-analysis 
Data synthesis can be done qualitatively; this is so-called descriptive systematic 
review, or quantitatively by using statistical techniques such as meta-analysis. A 
common criticism of meta-analyses is that they combine “apples and oranges” 
(Moayyedi 2004). Indeed, when the included studies are too heterogeneous, only 
descriptive synthesis should be undertaken instead of meta-analysis. Heterogeneity 
can result from either methodological (e.g. study design, study quality) or clinical (e.g. 
age, sex, study location, dose of the intervention) differences between studies. 
Nevertheless, when meta-analysis is possible, descriptive synthesis may also be 
required and can be effectively incorporated into the quantitative review. 
Two main statistical models can be used to combine data: the fixed-effects model 
and the random-effects model. Fixed-effects model assumes that every study is 
evaluating a common treatment effect. In other words, the effect of treatment, 
allowing for the play of chance, is the same in all studies. This model is generally 
used if there is no heterogeneity in the meta-analysis. The random-effects model is 
an alternative approach of meta-analysis; it assumes that the true treatment effect 
may vary across the individual studies because the difference between studies. If 
there is any concern about heterogeneity, the random-effects model is proposed 
(Zlowodzki et al. 2007). 
Dichotomous or binary outcome data arise when the outcome is one of two 
possibilities. The most frequently used measures for dichotomous data are the odds 
ratio, the risk ratio, the risk difference and the number needed to treat. Continuous 
outcomes can take any value on a scale that is continuously variable, and can be 
presented either as a mean difference (MD) or as a standardized mean difference 
(SMD). The MD measures the absolute differences between the mean values in two 
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groups. The SMD can be used when the studies assess the same outcome, but 
measure it using different scales (Zlowodzki et al. 2007). 
Forest plot (also known as ‘blocks and lines plot’, ‘confidence interval plot’ or 
‘blobbogram’) is typically used to present a good visual summary of the results of the 
meta-analysis (Figure 2). Individual studies are represented by a horizontal line 
extending either side of a square at the point estimate of treatment effect. The ends 
of the line represent the confidence interval (CI) (usually 95%, but other intervals can 
also be used). The area of each square is proportional to the weight assigned to that 
study in the meta-analysis. The pooled effects size from the meta-analysis is at the 
bottom of the plot, represented by a diamond. The centre of the diamond represents 
the pooled point estimate, and the horizontal tips of the diamond represent its CI. 
 
 
 
 
Figure 2: Hypothetical example of a forest plot with continuous outcome parameter 
(analysis done with the Review Manager 5.1 software) 
If the horizontal line for any study does not cross the line of no effect, it means that 
there is a significant difference between treatment and control groups. If the 
horizontal line for any study reaches or crosses the line of no effect, it means that 
there is no significant difference between the two groups. The same statement is true 
for the pooled effect size.  
Study or Subgroup
Study 1.
Study 2.
Study 3.
Study 4.
Study 5.
Study 6.
Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 9.02, df = 5 (P = 0.11); I² = 45%
Test for overall effect: Z = 7.61 (P < 0.00001)
Mean
2.7
2.9
2.75
3.16
2.85
2.3
SD
2.08
1.3
1.44
0.4
1.96
1.07
Total
15
112
12
24
231
9
403
Mean
1.9
2.2
1.32
2.03
1.59
1.61
SD
1.24
0.6
0.38
0.77
1.1
1.24
Total
16
53
11
25
195
10
310
Weight
4.3%
28.6%
8.0%
25.2%
28.2%
5.7%
100.0%
IV, Random, 95% CI
0.80 [-0.42, 2.02]
0.70 [0.41, 0.99]
1.43 [0.58, 2.28]
1.13 [0.79, 1.47]
1.26 [0.96, 1.56]
0.69 [-0.35, 1.73]
1.03 [0.76, 1.29]
Treatment Control Mean Difference Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours treatment
% weight of the 
individual studies individual studies 
line of no effect pooled effect size 
data shown in the graph 
are also given numerically 
(mean, [95% confidence interval]) 
scale measuring 
the treatment 
effect 
data of each studies, 
divided into treatment 
and control groups 
measure of 
heterogeneity 
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2. Aims 
 
 
As the importance of nutrition is increasingly recognised, clinical nutrition is now 
integrated into the mainstream medical treatment. In parallel with this, the use of 
systematic reviews for nutrition-related topic becomes more widespread. Currently, if 
the results of a study show no relation between micronutrient status and health 
outcome, it is not clear if the lack of relation is due to the biomarker being an 
inadequate measure of status or the absence of any relation between status and the 
health outcome. Use of biomarkers that reflect changes in micronutrient status can 
facilitate the understanding of the relationship between micronutrient intake and 
status and it follows from this, the relationship between micronutrient status and 
health outcome (Hooper et al. 2009). 
The risk of low dietary zinc intake, consequently zinc deficiency is widespread 
problem affecting between one-third and one-half of the world’s population (Brown et 
al. 2001). In European populations, severe primary zinc deficiency is extremely 
uncommon, but marginal deficiency is likely to be much more prevalent (Gibson et al. 
2008). The lack of a reliable, responsive, and specific indicator of zinc status means 
that the diagnosis of marginal zinc deficiency is difficult. Therefore, our aim was to 
perform a systematic review to assess the usefulness of the biomarkers of zinc status 
in healthy humans to determine which biomarkers appropriately reflect changes in 
zinc status in response to supplementation or depletion. 
In contrast to various micronutrients, it is not fatty acid deficiency that generates 
public interest in n-3 long-chain polyunsaturated fatty acid (LCPUFA) 
supplementation, rather the potential health benefits attributed to enhanced n-3 
LCPUFA intake. However, there are no generally accepted, gold standard 
biomarkers that reflect n-3 LCPUFA status in a specific and sensitive way (Baylin and 
Campos 2006). Accordingly, our aim was to conduct a systematic review of 
intervention studies with n-3 LCPUFA in healthy humans to identify the biomarkers of 
status that reliably reflect change in n-3 LCPUFA intake. 
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3. Assessing potential biomarkers of zinc status in 
humans: a systematic review 
 
 
3.1 Introduction 
Zinc is well established as an essential micronutrient for human health because it has 
numerous structural and biochemical functions at the cellular and subcellular level, 
which include enzyme function, DNA and RNA metabolism, protein synthesis, gene 
expression, cell growth and differentiation, and cell-mediated immunity. The 
ubiquitous nature of zinc in human biological systems indicates the widespread 
consequences and the complexity of inadequate dietary supply of zinc and zinc 
depletion. 
Rich sources of dietary zinc include meat, fish, seafood, nuts, seeds, legumes, and 
whole-grain cereals (Table 2). However, plant sources are considered to be less 
bioavailable because of the presence of phytic acid that binds to zinc-forming 
insoluble complexes, which thus inhibits zinc’s absorption (Brown et al. 2001). 
Table 2: Zinc and phytate content in foods and estimated amount of absorbable zinc 
Diets with a phytate:zinc molar ratio less than 5 have relatively good zinc bioavailability (45% to 55% 
of zinc is absorbed); between 5 and 15 have medium zinc bioavailability (30% to 35% of zinc is 
absorbed); greater than 15 have relatively poor zinc bioavailability (10% to 15% of zinc is absorbed). 
Adopted and modified from Brown et al. 2001. 
  
Food group 
Zinc content 
(mg/100 g) 
Phytate content 
(mg/100 g) 
Phytate:zinc 
molar ratio 
Absorbable zinc 
(mg/100 g) 
Liver, kidney (beef, poultry) 4.2–6.1 0 0 2.1–3.1 
Meat (beef, pork) 2.9–4.7 0 0 1.4–2.4 
Poultry 1.8–3.0 0 0 0.9–1.5 
Seafood 0.5–5.2 0 0 0.2–2.6 
Eggs 1.1–1.4 0 0 0.6–0.7 
Dairy products 0.4–3.1 0 0 0.2–1.6 
Seeds, nuts 2.9–7.8 1760–4710 22–88 0.3–0.8 
White bread 0.9 30 3 0.4 
Whole-grain cereals 0.5–3.2 211–618 22–53 0.1–0.3 
Legumes 1.0–2.0 110–617 19–56 0.1–0.2 
Refined cereal grains 0.4–0.8 30–439 16–54 0.1 
Tubers 0.3–0.5 93–131 3–27 <0.1–0.2 
Vegetables 0.1–0.8 0–116 0–42 <0.1–0.4 
Fruits 0–0.2 0–63 0–? <0.1–0.2 
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Current recommendations for dietary zinc intake in adults range from 7 mg/day (UK 
Reference Nutrient Intake) to 11 mg/day (US Recommended Dietary Allowance) 
(Geissler and Powers 2005). This broad range reflects in part the variation in 
requirements due to differences in the bioavailability of zinc from different national 
diets and also the difficulties associated with estimating the requirements for optimal 
health, which depends on a reliable indicator of status (King 1990). 
Unlike other micronutrients such as iron, there is no storage form of zinc in the body 
that can be readily mobilized when intakes are inadequate, which emphasizes the 
need for a regular dietary supply (King et al. 2001). A highly effective homeostatic 
mechanism responds to alterations in zinc intake, upregulating absorption and 
conserving losses via the gastrointestinal tract and kidneys when intakes fall. By 
using isotope tracer techniques, it was predicted that when dietary zinc fell from 12.2 
to 0.23 mg/day in a group of adult men, fractional zinc absorption could increase to 
virtually 100%, with urinary excretion falling from 0.36 to 0.006 mg/day and fecal 
excretion falling from 11.8 to 0.23 mg/day (King et al. 2001). When homeostatic 
mechanisms fail to ensure that requirements are met, clinical symptoms of zinc 
deficiency ensue. Severe deficiency is associated with stunted growth, immune 
dysfunction, and poor wound healing. These symptoms of severe zinc deficiency are 
most dramatically observed in acrodermatitis enteropathica, a congenital condition in 
which the infant is born with impaired gastrointestinal zinc transport, which limits the 
ability to absorb zinc (Atherton et al. 1979).  
 
 
3.2 Methods 
3.2.1. Inclusion criteria 
To be included, a study needed to meet all of the following criteria: 1) be an 
intervention study in humans (including supplementation and/or depletion studies) 
without restriction in study design, which could include RCTs, controlled clinical trials, 
and before-after studies (B/A); 2) report the zinc status in humans at baseline and 
after supplementation or depletion; 3) minimum duration of supplementation of 2 wk; 
4) report the daily dose of the zinc supplement; 5) use one of the following 
supplements: zinc sulphate; zinc acetate; zinc gluconate, or zinc methionine; and 6) 
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involve healthy participants who had not recently used mineral or vitamin 
supplements. 
 
3.2.2. Search strategy 
Electronic searches were performed with Ovid MEDLINE (www.ovid.com), EMBASE 
(Ovid) (www.ovid.com), and the Cochrane Library CENTRAL 
(www.thecochranelibrary.com) database, which were searched from inception to 
October 2007 for intervention studies by using text terms with appropriate truncation 
and relevant indexing terms. The search was in the form: [zinc terms] and 
[intervention study terms] and [human studies]. The OVID Medline search strategy 
can be found in Table 3, and the strategies for the other databases were based on 
the relevant OVID Medline strategy. We did not apply any language restriction. 
Table 3: Search strategy for Ovid MEDLINE from 1950 to October Week 3, 2007 
# Search History Results 
1 Zinc Sulfate/ 1082 
2 ((zinc$ or Zn$) adj1 sulphate$).mp.  569 
3 ((zinc$ or Zn$) adj1 sulfate$).mp.  1681 
4 Zinc Acetate/ 99 
5 ((zinc$ or Zn$) adj1 acetate$).mp.  396 
6 ((zinc$ or Zn$) adj1 gluconate$).mp.  138 
7 ((zinc$ or Zn$) adj1 methionine$).mp.  56 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 2543 
9 exp clinical trials/ or feasibility studies/ or intervention 
studies/ or pilot projects/ 
267783 
10 interven$.mp.  303162 
11 Dietary Supplements/ 13542 
12 supplement$.mp. 133439 
13 9 or 10 or 11 or 12 671914 
14 8 and 13 542 
15 ((zinc$ or Zn$) adj5 deplet$).mp. 581 
16 14 or 15 1109 
17 (animals not humans).sh. 3197957 
18 16 not 17 652 
Abbreviations: $, truncation symbol; sh, subject heading word; adj, adjacent operator; 
mp = title, original title, abstract, name of substance word, subject heading word. 
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An Ovid MEDLINE search was conducted for reviews of the methods of assessing 
zinc status; 6 of these reviews (Wood 2000; Brown 1998, Brown 2002; Hotz et al. 
2003; Hambidge 2003; Thompson 1991) were collected in full text, and the reference 
lists were checked. Studies that appeared to be intervention studies but that had not 
been already assessed for inclusion were collected. 
One expert, Rosalind Gibson (University of Otago), was asked if she could suggest 
additional intervention studies for the review. She suggested additional articles for 
assessment and these were then subjected to the same criteria listed above before 
they were accepted for inclusion. 
 
3.2.3. Data collection and synthesis 
Titles and abstracts were screened for inclusion by a single reviewer. The full text of 
all articles collected was screened for inclusion by using an inclusion and exclusion 
form by 2 independent reviewers. Where the 2 reviewers disagreed, the study was 
discussed and a consensus decision was reached, or a third reviewer was asked to 
arbitrate. Data for each included study were extracted into a Microsoft Access 2003 
database file (Microsoft Corp, Redmond, WA) by a single reviewer. In doubtful cases, 
studies were discussed with the review team before beginning full data extraction 
and, in some cases, study authors were contacted for clarification. When necessary, 
units of measurement were converted to a standard form to facilitate comparison 
across studies.  
We used formal inclusion/exclusion criteria and applied standard operation 
procedures for data extraction, validity assessment and meta-analysis (Hooper et al. 
2009). Meta-analysis was carried out with Cochrane software, Review Manager 
version 4.2 (Cochrane Collaboration; www.cochrane.org), with random-effects model. 
A statistically significant result indicated that the marker was indeed responding to 
supplementation and/or depletion. Levels of the heterogeneity were noted 
(heterogeneity was considered significant where P < 0.1 on the chi-square test or I2 > 
50%). 
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Because there was a danger of categorizing some biomarkers as ineffective when 
there actually was a shortage of data, such that one would not expect a statistically 
significant effect size on pooling, we would declare a biomarker effective (statistically 
significant pooled effect size; P < 0.05) or ineffective (statistically insignificant pooled 
effect size; P ≥ 0.05) only where the pooling included ≥3 studies and ≥50 participants 
overall. Where there were <3 studies or <50 participants, it was stated that there 
were insufficient data to make a decision (Hooper et al. 2009). 
 
 
3.3. Results 
3.3.1. Study inclusion 
The flow diagram for this review is shown in Figure 3. A total of 1334 titles and 
abstracts were screened after electronic and bibliographic searches or were 
recommended by experts. Of these, 182 appeared potentially relevant and were 
collected as full-text articles to be assessed for inclusion, and 180 full-text articles 
were assessed (2 articles could not be traced); 48 studies were found to fulfill the 
inclusion criteria. One article had elements of both an RCT and a B/A in the study 
design (Abdulla and Svensson 1979) and one article contained a supplementation 
and a depletion study (Prasad et al. 1996). These data were analyzed as 2 separate 
studies, giving a total of 48 studies from 46 publications: 24 described RCT studies 
and 24 described B/A studies. In some cases, studies were further subdivided into 
data sets, when, for example, the study cohort was assigned to groups receiving 
different amounts of supplementation.  
 
  
16 
 
 
Figure 3: Flow diagram of systematic literature search on biomarkers of zinc status 
Abbreviations: ALP, alkaline phosphatase; MT, metallothionein; EC-SOD, extracellular superoxide 
dismutase; ACE, angiotensin-converting enzyme; NP, neutral phosphatase. 
 
3.3.2. Quality of included studies 
The characteristics of the studies included in the analysis are presented in Table 4 
(supplementation studies) and Table 5 (depletion studies). In terms of the distribution 
of the age of the population groups studied, 67% (32/48) of the studies were in 
healthy adults, and 19% (9/48) in elderly people. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Titles and abstracts that appeared 
potentially relevant, ordered as full text 
papers: 182 
Full papers not available: 2 
Titles and abstracts retrieved from 
electronic, bibliographic and expert 
searches: 1334 
Titles and abstracts very unlikely to be 
relevant: 1152 
Supplementation and depletion studies 
included: 
Plasma Zn: 40; 10 
Urinary Zn: 5; 4 
Erythrocyte Zn: 5; 2 
Platelet Zn: 2; 3 
Plasma ALP: 3; 3 
Mononuclear cell Zn: 4; 1 
Polymorphonuclear cell Zn: 5; 1 
Aminolevulinic acid dehydratase: 2; 0 
Erythrocyte MT: 2; 1 
Monocyte MT cDNA: 2; 0 
Salivary-sediment Zn: 1; 1 
Saliva Zn: 1; 0 
Mixed saliva Zn: 0; 1 
Plasma EC-SOD: 1; 0 
Plasma 5’-nucleotidase: 0; 1 
Lymphocyte ecto-5’-nucleotidase: 1; 0 
T lymphocyte MT-2A mRNA: 0; 1 
Hair Zn: 3; 0 
Nail Zn: 1; 0 
Plasma Zn flux: 0; 1 
Endogenous Zn excretion: 0; 1 
Exchangeable Zn pool: 0; 1 
Feces Zn: 0; 1 
Neutrophil Zn: 0; 3 
Lymphocyte Zn: 1; 2 
Plasma ACE: 0; 1 
Carbonic anhydrase: 0; 1 
Neutrophil ALP: 0; 1 
Neutrophil α-D-mannosidase: 0; 1 
Erythrocyte membrane Zn: 0; 1 
Erythrocyte membrane ALP: 0; 1 
Erythrocyte membrane NP: 0; 1 
Full papers included: 46 
Full papers assessed for inclusion: 180 
Papers excluded: 
Not supplementation or depletion 
studies: 12 
Non healthy subjects: 37 
Not only zinc supplementation: 8 
Baseline and later status or change not 
reported: 47 
Imprecise data: 24 
Not meeting criterion of minimal 
duration: 4 
Data previously presented in an included 
study: 2 
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There were 5 studies in pregnant or lactating women (Hunt et al. 1985; O’Brien et al. 
2007; Shaaban et al. 2005; Tamura et al. 1996; Tamura et al. 2001), one study in 
postmenopausal women (Milne et al. 1987), and one study in children and 
adolescents (Palin et al. 1979). There were no studies in infants, and none that 
selected for immigrant or low-socioeconomic groups. As discussed in the 
methodology article (Hooper et al. 2009), quality assessment was undertaken as part 
of the data extraction process. A summary of the reasons for dropping out in the 
intervention group, the methods of randomization, and compliance checking are 
summarized in Table 6. In the majority of studies, the reasons for dropping out and 
the method and outcome of compliance testing were not reported. In studies that 
claimed to be randomized, only 2 of 26 described the methods used. 
 
3.3.3. Biomarkers identified and evaluated 
In the 48 studies included in this review, a total of 32 potential zinc biomarkers, 17 
biomarkers of zinc status in zinc supplementation trials, and 25 biomarkers in zinc 
depletion trials were identified (Figure 3). A summary of all the biomarkers identified, 
including the number of studies, participants, and the results of the primary analysis 
where relevant is presented in Table 7. A large proportion of the studies included in 
this review measured plasma or serum zinc concentration, and for simplicity, here the 
term ‘‘plasma’’ will be used to refer to both. The results of the secondary analysis of 
biomarkers for which there were sufficient data for subgroup analysis are described 
below.  
 
3.3.3.1. Plasma zinc concentration 
Plasma zinc concentration was the most frequently investigated marker of zinc 
status, with a total of 40 data sets from 35 supplementation studies, which involved 
1375 participants and 10 data sets from 10 depletion studies involving 79 
participants. Combining data from the depletion and supplementation studies, 
primary analysis revealed an overall significant (P < 0.00001) response of plasma 
zinc concentration to dietary zinc intake (MD: 2.88 μmol/L; 95% CI: 2.24, 3.51; I2 = 
93.6%) (Table 7). However, the high level of heterogeneity in this primary analysis 
means that the biomarker responded differently in the included studies; the reasons 
for these differences were explored through subgrouping of studies by their different 
characteristics. 
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n
d
o
m
iz
e
d
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
A
b
d
u
lla
 a
n
d
 S
u
c
k
 1
9
9
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
A
ll
a
n
 e
t 
a
l.
 2
0
0
0
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
B
a
le
s
 e
t 
a
l.
 1
9
9
4
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
B
a
rr
ie
 e
t 
a
l.
 1
9
8
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
B
la
c
k
 e
t 
a
l.
 1
9
8
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
il
ln
e
s
s
 (
8
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
B
o
d
g
e
n
 e
t 
a
l.
 1
9
8
8
 
R
a
n
d
o
m
iz
e
d
, 
ra
n
d
o
m
 
n
u
m
b
e
r 
ta
b
le
s
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
8
7
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
C
ro
u
s
e
 e
t 
a
l.
 1
9
8
4
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
D
a
il
y
 r
e
c
o
rd
s
;>
9
5
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
e
m
e
tr
e
e
 e
t 
a
l.
 1
9
8
0
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
o
n
a
n
g
e
lo
 e
t 
a
l.
 2
0
0
2
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
u
c
h
a
te
a
u
 e
t 
a
l.
 1
9
8
1
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
F
ie
ld
 e
t 
a
l.
 1
9
8
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
F
is
c
h
e
r 
e
t 
a
l.
 1
9
8
4
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
F
re
e
la
n
d
-G
ra
ve
s
 e
t 
a
l.
 1
9
8
1
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
G
a
tt
o
 a
n
d
 S
a
m
m
a
n
 1
9
9
5
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
9
8
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
G
ri
d
e
r 
e
t 
a
l.
 1
9
9
0
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
G
u
p
ta
 e
t 
a
l.
 1
9
9
8
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
a
y
e
e
 e
t 
a
l.
 2
0
0
5
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
e
c
k
m
a
n
n
 e
t 
a
l.
 2
0
0
5
 
R
a
n
d
o
m
iz
e
d
; 
s
o
ft
w
a
re
 
p
ro
g
ra
m
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
in
in
g
e
r-
F
a
vi
e
r 
e
t 
a
l.
 2
0
0
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
≥
9
8
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
o
d
k
in
s
o
n
 e
t 
a
l.
 2
0
0
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
N
/A
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
o
ll
in
g
s
w
o
rt
h
 e
t 
a
l.
 1
9
8
7
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
u
n
t 
e
t 
a
l.
 1
9
8
5
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
 (
1
4
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
L
o
w
e
 e
t 
a
l.
 2
0
0
4
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
, 
la
c
k
 o
f 
c
o
m
p
lia
n
c
e
 (
7
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
L
u
k
a
s
k
i 
e
t 
a
l.
 1
9
8
4
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
M
a
h
a
ja
n
 e
t 
a
l.
 1
9
9
2
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
22 
 
 
T
a
b
le
 6
. 
(C
o
n
ti
n
u
e
d
) 
S
tu
d
ie
s
 
R
a
n
d
o
m
iz
e
d
?
 M
e
th
o
d
 
o
f 
ra
n
d
o
m
iz
a
ti
o
n
 
R
e
a
s
o
n
s
 f
o
r 
d
ro
p
o
u
ts
 b
y
 
in
te
rv
e
n
ti
o
n
 g
ro
u
p
 (
n
o
. 
o
f 
s
u
b
je
c
ts
) 
M
e
th
o
d
 f
o
r 
c
h
e
c
k
in
g
; 
R
e
s
u
lt
s
 o
f 
c
o
m
p
li
a
n
c
e
 c
h
e
c
k
 
R
is
k
 o
f 
b
ia
s
 
M
e
d
e
ir
o
s
 e
t 
a
l.
 1
9
8
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
il
ln
e
s
s
 (
8
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
M
il
n
e
 e
t 
a
l.
 1
9
8
7
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
S
tr
ic
t 
c
o
n
tr
o
l;
 N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
O
’B
ri
e
n
 e
t 
a
l. 
2
0
0
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
>
9
0
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
a
c
h
o
ti
k
a
rn
 e
t 
a
l.
 1
9
8
5
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
m
o
n
o
n
u
c
le
o
s
is
 (
2
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
a
li
n
 e
t 
a
l.
 1
9
7
9
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
e
re
tz
 e
t 
a
l.
 1
9
9
3
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
in
n
a
 e
t 
a
l.
 2
0
0
2
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
ra
s
a
d
 e
t 
a
l.
 1
9
9
6
 3
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
ra
s
a
d
 e
t 
a
l.
 1
9
9
6
 4
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
4
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
R
u
z
 e
t 
a
l.
 1
9
9
2
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
S
tr
ic
t 
c
o
n
tr
o
l;
 S
a
ti
s
fa
c
to
ry
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
a
m
m
a
n
 a
n
d
 R
o
b
e
rt
s
 1
9
8
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
S
id
e
 e
ff
e
c
ts
 (
6
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
h
a
a
b
a
n
 e
t 
a
l.
 2
0
0
5
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
N
/A
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
tu
r 
e
t 
a
l.
 1
9
9
6
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
S
id
e
 e
ff
e
c
ts
, 
p
e
rs
o
n
a
l 
re
a
s
o
n
s
 (
1
8
) 
N
/A
; 
≥
8
0
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
u
lli
va
n
 a
n
d
 C
o
u
s
in
s
 1
9
9
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
B
y
 c
o
n
s
u
m
p
ti
o
n
 i
n
 t
h
e
 p
re
s
e
n
c
e
 o
f 
a
 d
ie
ti
ti
a
n
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
u
lli
va
n
 e
t 
a
l.
 1
9
9
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
w
a
n
s
o
n
 e
t 
a
l.
 1
9
8
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
E
xc
e
ll
e
n
t 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
T
a
m
u
ta
 e
t 
a
l.
 1
9
9
6
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
7
8
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
T
a
m
u
ta
 e
t 
a
l.
 2
0
0
1
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
T
h
o
m
a
s
 e
t 
a
l.
 1
9
9
2
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
W
e
is
m
a
n
n
 e
t 
a
l.
 1
9
7
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
S
id
e
 e
ff
e
c
ts
, 
la
c
k
 o
f 
c
o
m
p
li
a
n
c
e
 (
7
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
Y
a
d
ri
c
k
 e
t 
a
l.
 1
9
8
9
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
A
b
b
re
vi
a
ti
o
n
s
: 
N
/A
, 
n
o
 a
va
ila
b
le
 d
a
ta
; 
1
, 
st
u
d
y
 1
.;
 2
, 
s
tu
d
y 
2
.;
 3
, 
d
e
p
le
ti
o
n
 s
tu
d
y;
 4
, 
s
u
p
p
le
m
e
n
ta
ti
o
n
 s
tu
d
y.
 
L
o
w
 r
is
k
 o
f 
b
ia
s
 m
e
a
n
t 
th
a
t 
th
e
 s
tu
d
y
 w
a
s
 r
a
n
d
o
m
iz
e
d
, 
th
e
 r
a
n
d
o
m
iz
a
ti
o
n
 m
e
th
o
d
 w
a
s
 a
t 
le
a
s
t 
p
a
rt
ia
lly
 d
e
s
c
ri
b
e
d
, 
re
a
s
o
n
s
 f
o
r 
a
n
d
 n
u
m
b
e
rs
 o
f 
d
ro
p
o
u
ts
 w
e
re
 
s
ta
te
d
 (
o
r 
th
e
re
 w
e
re
 n
o
 d
ro
p
o
u
ts
),
 a
n
d
 t
h
e
 m
e
th
o
d
 u
s
e
d
 t
o
 a
s
s
e
s
s
 c
o
m
p
li
a
n
c
e
 a
n
d
 s
o
m
e
 a
s
s
e
s
s
m
e
n
t 
o
f 
c
o
m
p
lia
n
c
e
 w
e
re
 r
e
p
o
rt
e
d
. 
A
ll 
o
th
e
r 
s
tu
d
ie
s
 w
e
re
 
c
o
n
s
id
e
re
d
 a
t 
m
o
d
e
ra
te
 o
r 
h
ig
h
 r
is
k
 o
f 
b
ia
s
. 
 
23 
 
 
T
a
b
le
 7
. 
P
ri
m
a
ry
 a
n
a
ly
s
e
s
 (
th
e
 g
re
a
te
s
t 
d
u
ra
ti
o
n
 a
n
d
 t
h
e
 g
re
a
te
s
t 
s
u
p
p
le
m
e
n
ta
ti
o
n
 d
o
s
e
) 
fo
r 
e
a
c
h
 o
f 
th
e
 i
d
e
n
ti
fi
e
d
 b
io
m
a
rk
e
rs
 f
o
r 
s
u
p
p
le
m
e
n
ta
ti
o
n
 w
it
h
 z
in
c
 a
n
d
 z
in
c
 d
e
p
le
ti
o
n
 
A
b
b
re
vi
a
ti
o
n
s
: 
N
/A
, 
n
o
 a
va
ila
b
le
 d
a
ta
; 
M
D
, 
m
e
a
n
 d
iff
e
re
n
c
e
; 
C
I,
 c
o
n
fid
e
n
c
e
 i
n
te
rv
a
l.
 
T
o
 c
la
im
 t
h
a
t 
a
 b
io
m
a
rk
e
r 
w
a
s
 e
ff
e
c
ti
ve
 (
re
fl
e
c
te
d
 c
h
a
n
g
e
 i
n
 s
ta
tu
s
) 
w
it
h
in
 a
 r
e
vi
e
w
, 
3
 c
o
n
d
it
io
n
s
 n
e
e
d
e
d
 t
o
 b
e
 m
e
t:
 1
) 
s
ta
ti
s
ti
c
a
l 
s
ig
n
if
ic
a
n
c
e
 w
it
h
in
 a
 f
o
re
s
t 
p
lo
t 
(9
5
%
 C
I 
d
id
 n
o
t 
in
c
lu
d
e
 0
 o
r 
P
 <
0
.0
5
),
 2
) 
≥
3
 t
ri
a
ls
 c
o
n
tr
ib
u
ti
n
g
 d
a
ta
, 
a
n
d
 3
) 
≥
5
0
 p
a
rt
ic
ip
a
n
ts
 c
o
n
tr
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The summary of the subgroup analysis of the response of plasma zinc concentration 
to zinc supplementation and depletion is given in Table 8. The data included in this 
analysis were mostly collected from studies in adults and the elderly. The response of 
plasma zinc concentration to intervention was significant in adults, the elderly, 
pregnant and lactating women, men, women, mixed-sex groups and in those with a 
low or moderate zinc status at baseline, but there were insufficient data to draw firm 
conclusions on children and adolescents or on postmenopausal women. Data from 2 
studies suggest that individuals with high baseline status do not respond to 
supplementation, but further studies are required. Sulfate, gluconate, and acetate all 
elicited a significant response, although there were only 2 studies of acetate. 
Subgroup analysis revealed a significant fall in plasma zinc concentration in response 
to marginally depleted diet; all levels of zinc supplementation resulted in a significant 
increase in plasma zinc concentration and the MD in plasma zinc concentration 
increased in a dose-dependent manner (Figure 4). Overall, plasma zinc appears to 
be a good marker of zinc status in all subgroupings for which we have sufficient 
studies to judge. 
 
3.3.3.2. Urinary zinc excretion 
Data on the response of urinary zinc excretion to changes in dietary intake were 
extracted from 5 supplementation and 4 depletion studies, comprising 6 studies in 
adults (47 individuals from supplementation studies and 25 individuals from depletion 
studies), 2 studies in elderly people (both supplemented, with a total of 326 
participants), and one depletion study in postmenopausal women (5 participants). 
However, the units used for supplementation studies (mmol/mol creatinine) differed 
from those in the depletion studies (μmol/day), so only the supplementation studies 
could be pooled. Primary analysis (highest dose arm and longest duration for each 
included study) of the supplementation studies revealed a significant effect of zinc 
intake on urinary zinc excretion (MD: 0.31 mmol/mol creatinine; 95% CI: 0.20, 0.43) 
without important heterogeneity (I2 = 0%) and was supported by depletion studies 
(MD: 3.89 μmol/day; 95% CI: 1.01, 6.76; I2 = 93%) (Table 7). 
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Figure 4: Secondary analysis of the response of plasma zinc concentration (μmol/L) 
to zinc supplementation with subgrouping by dose (mg/day) 
Specification of the groups as represented in the original articles: x, study 1; xx, study 2; A, 15-mg 
Zn/day group; B, 30-mg Zn/day group; C, 45-mg Zn/day group; D, 50-mg Zn/day group; E, 75-mg 
Zn/day group; F, 100-mg Zn/day group; G, 150-mg Zn/day group; 1, endurance-trained male group; 2, 
sedentary male group; 3, male group (20–40 yrs); 4, female group (20–40 yrs); 5, female group (20–
40 yrs + oral contraceptive); 6, female group (40–50 yrs); 7, male group; 8, female group. 
Study or Subgroup
1.2.1 supplementation: 15 to 25 mg Zn/day
Abdulla & Suck 1998 A
Bogden et al. 1988 A
Donangelo et al. 2002
Heckmann et al. 2005
Hininger-Favier 2007 A
Hodkinson et al. 2007 A
Hunt et al. 1985
O'Brien et al. 2007
Palin et al. 1979
Tamura et al. 1996
Tamura et al. 2001
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 19.73, df = 10 (P = 0.03); I² = 49%
Test for overall effect: Z = 4.26 (P < 0.0001)
1.2.2 supplementation: 26 to 50 mg Zn/day
Abdulla & Suck 1998 B
Abdulla & Suck 1998 C
Abdulla & Svensson 1979xx
Barrie et al. 1987
Black et al. 1988 D
Crouse et al. 1984 1
Crouse et al. 1984 2
Field et al. 1987 D
Fischer et al. 1984
Gatto & Samman 1995
Hininger-Favier 2007 B
Hodkinson et al. 2007 B
Medeiros et al. 1987 D
Pachotikarn et al. 1985
Perezt et al. 1993
Prasad et al. 1996
Stur et al. 1996
Sullivan & Cousins 1997
Sullivan et al. 1998
Swanson et al. 1988
Yadrick et al. 1989
Subtotal (95% CI)
Heterogeneity: Tau² = 1.81; Chi² = 82.71, df = 20 (P < 0.00001); I² = 76%
Test for overall effect: Z = 6.98 (P < 0.00001)
1.2.3 supplememntation: 51 to 100 mg Zn/day
Black et al. 1988 E
Bogden et al. 1988 F
Demetree et al. 1980
Field et al. 1987 F
Hollingsworth et al. 1987
Medeiros et al. 1987 E
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.00, df = 5 (P = 0.55); I² = 0%
Test for overall effect: Z = 7.82 (P < 0.00001)
1.2.4 supplementation: 101 to 150 mg Zn/day
Abdulla & Svensson 1979x
Duchateau et al. 1981 3
Duchateau et al. 1981 4
Duchateau et al. 1981 5
Duchateau et al. 1981 6
Field et al. 1987 G
Gupta et al. 1998
Hayee et al. 2005
Samman & Roberts 1987 7
Samman & Roberts 1987 8
Weismann et al. 1977
Subtotal (95% CI)
Heterogeneity: Tau² = 19.48; Chi² = 116.94, df = 10 (P < 0.00001); I² = 91%
Test for overall effect: Z = 3.51 (P = 0.0005)
Mean
13.91
13.1
12.01
12.47
14
13
9.68
13.29
13.98
9.1
9.9
14.53
15.75
19.11
8.35
15.5
23.85
26.45
11.91
18.35
15.2
15.1
14.3
15.44
16.06
18.4
18.07
16.62
15
14.5
16.5
16.2
18.1
16.8
14.07
11.98
20.03
18.04
27.4
22.02
20.49
17.89
18.5
17.76
15.75
16.39
20.6
23.2
18.15
SD
1.53
2.1
1.64
3
2.6
2.49
1.41
1.71
5.93
0.17
2.2
1.68
1.99
2.29
0.58
1.62
6.6
7.65
1.96
5.5
4
3.6
4.49
5.79
2.75
2
5.22
4.02
2.43
2
2.47
3.3
4.05
3.5
6.27
2.43
4.89
5.83
1.5
7.65
5.05
5.96
4.9
5.15
5.4
4.85
4.6
6.3
4.49
Total
15
32
11
24
126
28
56
16
7
70
30
415
15
15
7
15
13
11
12
5
13
10
131
34
13
23
9
5
38
10
11
17
9
416
9
32
5
5
8
9
68
7
20
20
23
20
5
20
20
21
20
13
189
Mean
11.77
12.5
10.26
11.01
13
12.4
9.14
13.2
13.76
8.73
9.7
12.39
12.39
13.76
8.39
13.5
21.56
23.39
11.15
15.14
12.8
13
12.4
13.46
11.62
14.2
17.48
13.04
12.3
13
12.9
12.9
13.5
12.5
8.1
10.31
14.22
13.46
15.2
16.82
15.14
14.07
13.61
11.83
15.78
16.53
15.1
14.8
15.39
SD
2.14
2
1.45
1.56
1.7
1.59
1.25
1.41
1.96
0.16
1.7
2.29
2.14
1.53
1.17
1.05
5.2
5.2
1.42
0.83
2.4
1.7
1.56
5.83
2
1.8
1.98
1.56
2.43
1
1.65
1.8
1.05
2
2.75
2.38
1.68
5.83
1
4.43
3.37
3.52
4.74
1.7
5.44
3.48
2.5
2.5
2.12
Total
15
32
11
26
130
31
47
10
10
65
31
408
15
15
7
15
9
10
11
5
13
10
130
31
9
23
9
8
42
10
11
17
9
409
9
32
5
5
8
9
68
5
20
20
23
20
5
20
20
21
20
12
186
Weight
4.8%
7.5%
5.1%
4.8%
15.2%
6.7%
15.9%
5.6%
0.5%
26.2%
7.6%
100.0%
6.0%
5.9%
4.8%
7.3%
6.5%
1.6%
1.5%
4.7%
3.3%
3.5%
7.2%
5.6%
1.7%
6.0%
5.3%
1.8%
6.1%
4.7%
6.2%
6.0%
4.1%
100.0%
14.9%
57.0%
3.1%
12.5%
8.7%
3.8%
100.0%
9.9%
8.5%
9.3%
9.2%
9.1%
7.8%
8.9%
9.3%
9.6%
9.1%
9.3%
100.0%
IV, Random, 95% CI
2.14 [0.81, 3.47]
0.60 [-0.40, 1.60]
1.75 [0.46, 3.04]
1.46 [0.12, 2.80]
1.00 [0.46, 1.54]
0.60 [-0.48, 1.68]
0.54 [0.03, 1.05]
0.09 [-1.12, 1.30]
0.22 [-4.34, 4.78]
0.37 [0.31, 0.43]
0.20 [-0.79, 1.19]
0.70 [0.38, 1.03]
2.14 [0.70, 3.58]
3.36 [1.88, 4.84]
5.35 [3.31, 7.39]
-0.04 [-0.70, 0.62]
2.00 [0.88, 3.12]
2.29 [-2.77, 7.35]
3.06 [-2.25, 8.37]
0.76 [-1.36, 2.88]
3.21 [0.19, 6.23]
2.40 [-0.49, 5.29]
2.10 [1.42, 2.78]
1.90 [0.29, 3.51]
1.98 [-2.96, 6.92]
4.44 [3.05, 5.83]
4.20 [2.44, 5.96]
0.59 [-4.19, 5.37]
3.58 [2.22, 4.94]
2.70 [0.57, 4.83]
1.50 [0.18, 2.82]
3.60 [2.19, 5.01]
3.30 [0.84, 5.76]
2.61 [1.88, 3.34]
4.60 [1.87, 7.33]
4.30 [2.90, 5.70]
5.97 [-0.03, 11.97]
1.67 [-1.31, 4.65]
5.81 [2.23, 9.39]
4.58 [-0.81, 9.97]
4.21 [3.15, 5.26]
12.20 [10.78, 13.62]
5.20 [1.33, 9.07]
5.35 [2.69, 8.01]
3.82 [0.99, 6.65]
4.89 [1.90, 7.88]
5.93 [1.18, 10.68]
-0.03 [-3.39, 3.33]
-0.14 [-2.76, 2.48]
5.50 [3.26, 7.74]
8.40 [5.43, 11.37]
2.76 [0.04, 5.48]
4.94 [2.18, 7.70]
Intervention Control Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Intervention lower Intervention higher
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Significant responses were recorded in studies of adults, the elderly, males, mixed-
sex groups, females and in those with a low or moderate zinc status at baseline; 
however, there were enough studies (≥3) and participants (≥50) to declare urinary 
zinc a useful marker of zinc status only in those with moderate status at baseline 
(Table 9). All of the supplementation trials that measured urinary zinc concentration 
used zinc gluconate, with 3 data sets (326 participants) in the 15–25 mg Zn/day 
range, 4 data sets (370 participants) in the 26–50 mg Zn/day range, and 2 data sets 
(36 participants) in the 51–100 mg Zn/day range. A statistically significant increase in 
urinary zinc excretion was seen in response to all 3 dose ranges, but only the 15–25 
and the 26–50 mg Zn/day subgroups included enough studies to declare the marker 
useful. The data do suggest a dose response (Figure 5). 
Table 9: Subgroup analysis of the results of the systematic review of data on 
changes in urinary zinc after supplementation with zinc 
 
See details below Table 8. 
  
 
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity 
I
2
 
Biomarker 
useful? RCTs B/A 
 
mmol/mol creatinine no. of studies (no. of participants) %  
All studies (primary outcome) 0.31 [0.20, 0.43] 4 (362) 1 (11) 0 Yes 
Adults 0.33 [0.10, 0.56] 2 (36) 1 (11) 0 Unclear 
The elderly 0.31 [0.18, 0.44] 2 (326) N/A 0 Unclear 
Males 0.61 [0.07, 1.15] 2 (36) N/A 0 Unclear 
Mixed 0.31 [0.18, 0.44] 2 (326) N/A 0 Unclear 
Females 0.27 [0.02, 0.52] N/A 1 (11) N/A Unclear 
Low status at baseline 0.27 [0.02, 0.52] N/A 1 (11) N/A Unclear 
Moderate status at baseline 0.33 [0.20, 0.45] 4 (362) N/A 0 Yes 
Zinc gluconate 0.31 [0.20, 0.43] 4 (362) 1 (11) 0 Yes 
15 to 25 mg Zn/day 0.15 [0.04, 0.25] 2 (315) 1 (11) 0 Yes 
26 to 50 mg Zn/day 0.32 [0.20, 0.45] 4 (370) N/A 0 Yes 
51 to 100 mg Zn/day 0.62 [0.07, 1.16] 2 (36) N/A 0 Unclear 
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Figure 5: Secondary analysis of the response of urinary zinc excretion to zinc 
supplementation (mmol/mol creatinine) with subgrouping by dose (mg/day) 
Specification of the groups as represented in the original articles: A, 15-mg Zn/day group; 
B, 30-mg Zn/day group; D, 50-mg Zn/day group; E, 75-mg Zn/day group. 
 
3.3.3.3. Erythrocyte zinc concentration 
A total of 5 supplementation and 2 depletion studies reported values for erythrocyte 
zinc concentration. Neither primary analysis (MD: 2.20 μmol/L; 95% CI: -4.58, 8.98; I2 
= 0%) nor any individual study suggested a response of this biomarker to changes in 
zinc intake. For more subgroup analysis details see Table 10. These data suggest 
that erythrocyte zinc concentration is not a useful marker of zinc status 
 
3.3.3.4. Platelet zinc concentration 
Five studies that measured platelet zinc concentration (2 supplementation RCTs and 
3 depletion B/A studies) were identified. The primary analysis, combining data from 
supplementation and depletion studies, did not reveal a significant response to 
changes in dietary zinc intake (MD: 0.09 nmol/109 cells; 95% CI: -1.12, 1.30; I2 = 
76%) (Table 7). 
Study or Subgroup
2.1.1 supplementation: 15 to 25 mg Zn/day
Donangelo et al. 2002
Hininger-Favier 2007 A
Hodkinson et al. 2007 A
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.21, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 2.66 (P = 0.008)
2.1.2 supplementation: 26 to 50 mg Zn/day
Black et al. 1988 D
Hininger-Favier 2007 B
Hodkinson et al. 2007 B
Medeiros et al. 1987 D
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.48, df = 3 (P = 0.92); I² = 0%
Test for overall effect: Z = 5.10 (P < 0.00001)
2.1.3 supplementation: 51 to 100 mg Zn/day
Black et al. 1988 E
Medeiros et al. 1987 E
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 2.22 (P = 0.03)
2.1.4 supplementation: 101 to 150 mg Zn/day
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Mean
0.83
0.94
0.62
0.99
1.13
0.9
1.14
1.13
1.3
SD
0.37
0.5
2.86
0.84
0.59
5.31
1.34
0.94
1.2
Total
11
126
28
165
13
131
34
13
191
9
9
18
0
Mean
0.56
0.82
0.8
0.54
0.82
0.8
0.62
0.54
0.6
SD
0.22
0.47
4.45
0.16
0.47
4.45
1.2
0.16
1.2
Total
11
130
31
172
9
130
31
9
179
9
9
18
0
Weight
17.9%
81.8%
0.3%
100.0%
7.0%
91.4%
0.3%
1.3%
100.0%
76.0%
24.0%
100.0%
IV, Random, 95% CI
0.27 [0.02, 0.52]
0.12 [0.00, 0.24]
-0.18 [-2.07, 1.71]
0.15 [0.04, 0.25]
0.45 [-0.02, 0.92]
0.31 [0.18, 0.44]
0.10 [-2.27, 2.47]
0.52 [-0.55, 1.59]
0.32 [0.20, 0.45]
0.59 [-0.03, 1.21]
0.70 [-0.41, 1.81]
0.62 [0.07, 1.16]
Not estimable
Intervention Control Mean Difference Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Intervention lower Intervention higher
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Table 10: Subgroup analysis of the results of the systematic review of data on 
changes in erythrocyte zinc after supplementation with zinc and zinc depletion 
 
See details below Table 8. 
 
3.3.3.5. Plasma alkaline phosphatase activity 
Six studies investigating the response of plasma alkaline phosphatase activity to 
changes in zinc intake were included: 3 supplementation (RCTs) and 3 depletion 
(B/A) studies. Overall, the primary analysis, combining the supplementation and 
depletion trials, revealed no significant effect of zinc intakes on plasma alkaline 
phosphatase activity (MD: 4.14 IU/L; 95% CI: -2.38, 10.65; I2 = 56.6%), which 
suggests that this is not a useful zinc biomarker. Subgrouping also did not reveal any 
groups in which this was a clearly useful biomarker of zinc status (Table 11). 
 
3.3.3.6. Mononuclear cell zinc concentration 
Five studies, including 95 participants, assessed the effect of the change in zinc 
intake on mononuclear cell zinc concentration. Pooling these 5 studies suggested 
that this is not a useful biomarker of zinc status (MD: -0.05 μmol/1010 cells; 95% CI: -
0.21, 0.11; I2 = 38%) (Table 7). 
  
 
Analysis   
Pooled effect size   
MD (95% CI)    
Study design   
Heterogeneity 
I 2   
Biomarker  
useful?   
RCT  
supplementation   
B/A   
depletion   
  µmol/L   no. of studies (no. of participants)   %     
All studies (primary outc ome)   2.20 [ - 4.58, 8.98]   5 (527)   2 (10)   0   No   
Pregnancy and lactation   3.80 [ - 8.51, 16.10]   2 (186)   N/A   0   Unclear   
Adults   - 1.36 [ - 13.34, 10.62]   1 (15)   1 (5)   0   Unclear   
Post - menopausal women   - 6.00 [ - 28.49, 16.49]   N/A   1 (5)   N/A   Unclear   
The elderly   5.30 [ - 12.49 , 23.09]   2 (326)   N/A   39.2   Unclear   
Males   - 2.40 [ - 22.36, 17.56]   N/A   1 (5)   N/A   Unclear   
Mixed   3.62 [ - 6.82, 14.07]   3 (341)   N / A   11.6   No   
Females   1.54 [ - 9.26, 12.33]   2 (186)   1 (5)   0   No   
Low status at baseline   1.96 [ - 7.55, 11.47]   3 (201)   N/A   0   No   
Moderate status  at baseline   2.45 [ - 7.22, 12.12]   2 (326)   2 (10)   0   No   
Zinc sulphate   3.80 [ - 8.51, 16.10]   2 (186)   X   0   Unclear   
Zinc gluconate   3.62 [ - 6.82, 14.07]   3 (341)   X   11.6   No   
1 to 2.9 mg Zn/day   - 6.00 [ - 28.49, 16.49]   X   1 (5)   N/A   Unclear   
3 to 5 mg Zn/day   - 2.40 [ - 22.36,  17.56]   X   1 (5)   N/A   Unclear   
15 to 25 mg Zn/day   25.17 [ - 6.01, 56.36]   4 (501)   X   91.2   No   
26 to 50 mg Zn/day   3.62 [ - 6.82, 14.07]   3 (341)   X   11.6   No   
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Table 11: Subgroup analysis of the results of the systematic review of data on 
changes in plasma alkaline phosphatase activity after supplementation with zinc and 
zinc depletion 
 
See details below Table 8. 
 
3.3.3.7. Polymorphonuclear cell zinc concentration 
Five supplementation trials and one depletion study that measured 
polymorphonuclear cells as a biomarker of zinc status were identified. Population 
groups represented in the studies included adults (2 studies) and elderly persons (4 
studies). Individual studies were variable, which suggests both significantly positive 
and negative effects of increased zinc status on polymorphonuclear cell zinc 
concentration. Neither primary (MD: 0.05 μmol/1010 cells; 95% CI: -0.13, 0.22; I2 = 
83.3) nor subgroup analyses (Table 12) revealed any significant response of this 
biomarker to changes in zinc intake. Our data suggest that polymorphonuclear cell 
zinc concentration is not a useful marker of zinc status. 
  
 
Analysis   
Pooled effect size   
MD (95% CI)    
Study design   
Heterogeneity 
I 2   
Biomarker  
usefu l?   
RCT  
supplementation   
B/A   
depletion   
  IU/L   no. of studies (no. of participants)   %     
All studies (primary outcome)   4.14 [ - 2.38, 10.65]   3 (385)   3 (25)   56.6   No   
Pregnancy and lactation   12.00 [ - 11.81, 35.81]   1 (60)   N/A   N/A   Unclear   
Adults   21.80 [8.91, 34 .69]   N/A   1 (5)   N/A   Unclear   
Post - menopausal women   - 5.20 [ - 16.82, 6.42]   N/A   1 (5)   N/A   Unclear   
The elderly   1.22 [ - 2.39, 4.83]   2 (325)   1 (15)   0   No   
Males   21.80 [8.91, 34.69]   N/A   1 (5)   N/A   Unclear   
Mixed   1.22 [ - 2.39, 4.83]   2 (325)   1 (15)   0   No   
Females   0.13 [ - 15.46, 15.72]   1 (60)   1 (5)   38.3   Unclear   
Low status at baseline   12.00 [ - 11.81, 35.81]   1 (60)   N/A   N/A   Unclear   
Moderate status at baseline   3.68 [ - 3.26, 10.63]   2 (325)   3 (25)   63.2   No   
Zinc sulphate   12.00 [ - 11.81, 35.81]   1 (60)   X   N/A   Unclear   
Zinc gluconate   0 .90 [ - 3.47, 5.27]   1 (261)   X   N/A   Unclear   
Zinc acetate   6.00 [ - 21.65, 33.65]   1 (64)   X   N/A   Unclear   
<1 mg Zn/day   21.80 [8.91, 34.69]   X   1 (5)   N/A   Unclear   
1 to 2.9 mg Zn/day   - 5.20 [ - 16.82, 6.42]   X   1 (5)   N/A   Unclear   
3 to 5 mg Zn/day   1.67 [ - 4.92, 8.26]   X   1 (15)   N/A   Unclear   
15 to 25 mg Zn/day   4.43 [ - 1.60, 10.45]   3 (380)   X   0   No   
26 to 50 mg Zn/day   0.90 [ - 3.47, 5.27]   1 (261)   X   N/A   Unclear   
51 to 100 mg Zn/day   6.00 [ - 21.65, 33.65]   1 (64)   X   N/A   Unclear   
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3.3.3.8. Hair zinc concentration 
Data were analyzed from 3 RCT supplementation studies, which included a total of 
93 adult participants with either low or moderate baseline status and intakes in the 
ranges of 15–25, 26–50, and 51–100 mg Zn/day. Primary analysis revealed that hair 
zinc concentration was significantly elevated after supplementation (MD: 13.24 ppm; 
95% CI: 11.91, 14.56; I2 = 0%) (Figure 7). Insufficient data precluded subgroup 
analyses. 
 
3.3.3.9. Other potential markers 
We found at least one study each to assess the effects of zinc supplementation or 
depletion on the following potential zinc biomarkers: aminolevulinic acid dehydratase, 
erythrocyte metallothionein, monocyte metallothionein cDNA, salivary-sediment zinc, 
salivary zinc, mixed-saliva zinc, plasma extracellular superoxide dismutase, plasma 
5’-nucleotidase, lymphocyte ecto-5’-nucleotidase, T lymphocyte metallothionein -2A 
mRNA, nail zinc, plasma zinc flux, endogenous zinc excretion, exchangeable zinc 
pool, fecal zinc, neutrophil zinc, lymphocyte zinc, plasma angiotensin-converting 
enzyme, carbonic anhydrase, neutrophil alkaline phosphatase, neutrophil α-D-
mannosidase, erythrocyte membrane zinc, erythrocyte membrane alkaline 
phosphatase, and erythrocyte membrane neutral phosphatase. However, there were 
not enough eligible studies of these markers to allow us to decide whether they were 
effective markers of zinc status (Table 7). 
 
 
3.4. Discussion 
Data were extracted and analyzed on 32 potential biomarkers from 46 publications. 
Plasma zinc concentration responded to dietary manipulation in adults, women, men, 
pregnant and lactating women, the elderly, and those at low and moderate baseline 
zinc status and in both depletion and supplementation studies. Urinary zinc excretion 
also appeared to respond to change in zinc status for all groups for which we had 
data, but with fewer studies there were fewer subgroupings with enough studies to 
make a clear decision about urinary zinc response. Hair zinc concentration also 
responded to zinc supplementation, but there were insufficient studies to assess in 
which subgroups these may be effective markers. For platelet, polymorphonuclear 
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cell, mononuclear cell, and erythrocyte zinc concentration and alkaline phosphatase 
activity, there were sufficient data to judge them as likely to be ineffective as 
biomarkers of zinc status. 
The majority of studies identified and included in this review were zinc 
supplementation studies that covered a broad range of zinc intake levels, which 
ranged from intakes that could be achieved through diet alone to pharmacologic 
doses at values of >10 times the European and US dietary recommendations. Fewer 
zinc depletion studies were identified, and participant numbers were low compared 
with the supplementation trials because of the practical and ethical difficulties of 
conducting depletion trials. 
The search for a reliable indicator for zinc has been problematic because the 
effective regulation of zinc homeostasis buffers the functional response to dietary 
deficiency and excess. The total amount of zinc present in the human body ranges 
from 1.5 to 2.5 mg, most of which is found intracellularly within skeletal muscle tissue 
(57%), bone (29%), and other tissues, including skin and organs (Jackson 1989). The 
zinc located within these tissues has a relatively slow turnover rate and is not readily 
responsive to changes in dietary zinc intake. Kinetic studies suggest that only a small 
proportion of total body zinc (≈10%) represents the ‘‘functional pool’’ (King 1990; 
Foster et al. 1979; Miller et al. 1994), which is composed of zinc, located within the 
liver and other tissues, that exchanges rapidly with the plasma. When this functional 
pool is depleted, zinc deficiency ensues (King 1990).  
All studies included in the analysis were undertaken in apparently healthy individuals. 
It is well established that plasma zinc concentration can fall in response to factors 
unrelated to zinc status or dietary zinc intake, including infection, inflammation, 
stress, or trauma. Conversely, tissue catabolism during starvation can release zinc 
into the circulation, causing a transient increase in circulating zinc levels. 
Furthermore, postprandial falls in plasma zinc concentration of ≤22% have been 
reported (Hambidge et al. 1989; Lowe et al. 1998). Clearly, the interpretation of 
plasma zinc concentration requires knowledge of all of these possible confounders. 
This review highlights a number of gaps in the field of zinc research. More high-
quality studies are required to assess the effects of most potential zinc biomarkers 
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and in a variety of populations. Ideally, these would be highly controlled studies or 
RCTs, with clearly presented methodology indicating that they are at low risk of bias. 
Studies need to describe their randomization methodology, clearly describe the 
numbers of dropouts or exclusions and the reasons for their cessation of inclusion, 
check compliance, and report the results of such checks. Further research is needed 
to evaluate potentially useful biomarkers, including enzymes and other zinc-binding 
proteins that were measured in only 1 or 2 studies and for which conclusions were 
unable to be drawn. Although stable isotope studies are expensive, technically 
demanding, and unsuitable for large population studies, they may be useful tools for 
evaluating more accessible potential biomarkers and to develop new biomarkers. 
There were some notable gaps in the availability of data from certain population 
groups; in particular, there was a complete absence of data regarding infants and 
immigrant population groups and a paucity of studies of zinc status in adolescents. 
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4. Assessing potential biomarkers of n-3 long-chain 
polyunsaturated fatty acid status in humans: a systematic 
review 
 
 
4.1. Introduction 
Long-chain polyunsaturated fatty acids (LCPUFAs) are important components of 
membrane lipids in all tissues. The most important of them are the n-6 (omega-6) 
essential fatty acid, linoleic acid (C18:2n-6, LA), and the n-3 (omega-3) essential fatty 
acid, α-linolenic acid (C18:3n-3, ALA), as well as their longer-chain metabolites, 
arachidonic acid (C20:4n-6, AA), eicosapentaenoic acid (C20:5n-3, EPA) and 
docosahexaenoic acid (C22:6n-3, DHA) (Figure 6). LCPUFAs increase the fluidity, 
flexibility and permeability of cell membranes, the number of receptors and the affinity 
of receptors to their substrates: hormones, growth factors, and proteins. Moreover, 
some LCPUFAs are also precursors of several second messengers (Das 2006). N-6 
fatty acids, mainly AA and dihomo-γ-linolenic acid (C20:3n-6), are predominantly 
precursors of proinflammatoric prostaglandins, thromboxans and leucotriens, while n-
3 fatty acids, mainly EPA, are precursors of antiinflammatory eicosanoids. AA and 
DHA are concentrated in the central nervous system, as well as in the retina, heart 
and skeletal muscle, and play an important role in the maintenance of normal 
development and normal neural functions (Das 2006).  
Mammals, including humans, cannot synthesize essential fatty acids; therefore they 
have to consume them in the diet from dietary sources. The enzymatic reactions of 
Δ-6- and Δ-5 desaturation and elongation of essential fatty acids convert LA to AA 
and ALA to EPA. While AA is the major product of the n-6 fatty acid family, EPA is an 
intermediate, which needs further elongation, Δ-6 desaturation and peroxysomal β-
oxidation to be converted into the biologically most important product, DHA (Figure 
6) (Infante and Huszagh 1997).  
Vegetables are good sources of essential fatty acids; however, their preformed long-
chain metabolites are found mainly in animal foods. Food products of terrestrial 
animals are rich in n-6 fatty acids, whereas sea fishes are rich in n-3 fatty acids (Kris-
Etherton et al. 2007). Although oily fish and various other seafoods are excellent 
dietary sources of EPA and DHA, dietary intake of n-3 LCPUFA (including DHA) in 
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the United States is only ≈110 mg/day in women and ≈170 mg/day in men (Gebauer 
et al. 2006). However, various dietary supplements containing several hundred 
milligrams of n-3 LCPUFAs per dose are widely available, so it is relatively easy to 
achieve a 10-fold increase in daily n-3 LCPUFA intake. 
 
Figure 6: Metabolism of the n-6 and n-3 fatty acids 
Adopted and modified from Giovannini et al. 1995. 
Many clinical studies have assessed the effect of n-3 LCPUFA supplementation in 
restoring health and maintaining well-being, and the medical relevance of the topic is 
underpinned by ≥15 Cochrane Database Systematic Reviews of n-3 LCPUFA 
supplementation. These systematic reviews assessed the affect of dietary n-3 
LCPUFA supplementation on preterm (Schulzke et al. 2011) and full-term infants 
(Simmer et al. 2008) as well as the potential role of n-3 LCPUFA adjuvant therapy in 
type 2 diabetes mellitus (Hartweg et al. 2008), cardiovascular disease (Hooper et al. 
2004), cancer cachexia (Dewey et al. 2007), Crohn’s disease (Turner et al. 2009), 
ulcerative colitis (Turner et al. 2007; De Ley et al. 2007), cystic fibrosis (Oliver et al. 
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2007), intermittent claudication (Sommerfield et al. 2007), asthma (Thien et al. 2002), 
schizophrenia (Irving et al. 2006), dementia (Lim et al. 2006), bipolar disorder 
(Montgomery et al. 2008), and multiple sclerosis (Farinotti et al. 2007) and in kidney 
transplant recipients (Lim et al. 2007). The majority of these reviews concluded that, 
although there is some indication of the beneficial effect of n-3 LCPUFA 
supplementation, further studies are needed to establish efficacy of intervention. 
One of the practical difficulties of designing and carrying out clinical trials 
investigating the effect of n-3 LCPUFA supplementation is the lack of a generally 
accepted biomarker that reflects increased n-3 LCPUFA status in response to 
enhanced dietary intake. This link is essential to deciding whether the negative 
outcome of a controlled trial, ie, lack of functional change in response to 
supplementation, can be related to either the basic hypothesis on clinical effect, lack 
of subject compliance, or the inability of dietary intervention to evoke changes in the 
fatty acid composition of relevant biological compartments within the body. It is even 
more important in epidemiologic studies assessing health effects of n-3 LCPUFA 
status in populations over long periods to understand which biomarkers truly reflect 
n-3 LCPUFA status. 
 
 
4.2. Methods 
4.2.1. Inclusion criteria 
To be included in the review, a study needed to meet all of the following 
characteristics: 1) an intervention study in humans (RCT, controlled clinical trial, or 
B/A study); 2) reported n-3 LCPUFA status at baseline and after supplementation; 3) 
involved supplementation with marine oils (fish, whale, or seal oil), seafoods (caviar 
or oily fish), single cell oils, or DHA-enriched eggs; 4) minimum duration of 
supplementation of 2 wk; 5) described a daily dose of n-3 LCPUFA supplement; and 
6) included participants who were healthy individuals. 
 
4.2.2. Search strategy 
Ovid MEDLINE (www.ovid.com), EMBASE (Ovid) (www.ovid.com), and the Cochrane 
Library CENTRAL database (www.thecochranelibrary.com) were searched from 
inception to September 2007 for intervention studies of n-3 LCPUFA using text terms 
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with appropriate truncation and relevant indexing terms. The search was in the form, 
[n-3 LCPUFA terms] and [intervention study terms] and [human studies]. The OVID 
Medline search strategy can be found in Table 13, and the strategies for the other 
databases were based on the relevant OVID Medline strategy. We did not apply any 
language restriction. 
An Ovid MEDLINE search was conducted for reviews of n-3 LCPUFA status 
assessment. Ten reviews were collected in full text and the reference lists checked 
(Arab 2003; Lands 1995; Baylin and Campos 2006; Katan et al. 1991; Fleith and 
Clandinin 2005, Carlson 1994; Innis 1992; Cantwell 2000; Morris 2003; Arterburn et 
al. 2006). Studies that appeared to be intervention studies but that had not been 
already assessed for inclusion were collected.  
Three experts on n-3 LCPUFAs were contacted (Carlo Agostoni, University of Milan; 
Berthold Koletzko, University of Munich; and Cristina Campoy, University of 
Granada). The aim of the review was explained and our current list of included 
studies forwarded with a request to suggest any additional studies they believed may 
have been appropriate for inclusion. These were assessed for inclusion according to 
the criteria listed above. 
  
39 
 
Table 13: Search strategy for Ovid MEDLINE from 1950 to September Week 2, 2007 
# Search History Results 
1 Eicosapentaenoic Acid/ 2615 
2 "eicosapent?enoic acid$".mp.  4224 
3 EPA.mp.  5110 
4 Docosahexaenoic Acids/ 3135 
5 "docosahex?enoic acid$".mp.  5140 
6 DHA.mp.  4360 
7 "docosapent?enoic acid$".mp.  393 
8 DPA.mp.  1159 
9 fish oils/ or cod liver oil/ or fatty acids, omega-3/ 8069 
10 "fish oil$".mp.  6008 
11 "cod liver oil$".mp.  562 
12 "icosapent?enoic acid$".mp. 22 
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 19650 
14 randomized controlled trial.pt. 242634 
15 controlled clinical trial.pt. 76223 
16 randomized controlled trials.sh. 51000 
17 random allocation.sh. 59065 
18 double blind method.sh. 93460 
19 single blind method.sh. 11340 
20 14 or 15 or 16 or 17 or 18 or 19 411123 
21 13 and 20 1906 
22 ("n-3" adj4 "FA$").mp.  4783 
23 ("n-3" adj4 "PUFA$").mp.  1435 
24 ("n3" adj4 "fatty$").mp.  64 
25 ("n3" adj4 "PUFA$").mp.  24 
26 "omega-3".mp.  6367 
27 exp fatty acids, omega-3/ or exp fish oils/ 12358 
28 omega3$.mp. 240 
29 22 or 23 or 24 or 25 or 26 or 27 or 28 15568 
30 deplet$.mp.  103076 
31 29 and 30 265 
32 21 or 31 2161 
33 (animals not humans).sh. 3181772 
34 32 not 33 1774 
 
Abbreviations: $, truncation symbol; ?, optional wild card character; adj, adjacent 
operator; exp, exploded subject heading word; pt, publication type; sh, subject heading 
word; mp = title, original title, abstract, name of substance word, subject heading word. 
 
4.2.3. Data collection and synthesis 
Titles and abstracts were screened for inclusion by a single reviewer. The high 
number of items to be evaluated made duplicate assessment at this stage unfeasible. 
The full text of all articles collected was screened for inclusion by using an 
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inclusion/exclusion form completed by 2 independent reviewers. Where the 2 
reviewers disagreed, the study was discussed and a consensus decision reached 
where possible. If this was not possible, then a third reviewer was asked to arbitrate. 
Data for each included study were extracted into a Microsoft Access 2003 database 
file (Microsoft Corp, Redmond, WA) by a single reviewer. In doubtful cases, studies 
were discussed with the review team before beginning full data extraction. Where 
necessary, units of measurement were recalculated to percentage contribution of n-3 
LCPUFA to total fatty acid composition of the relevant lipid fraction (% weight/weight). 
The data for the given fatty acid fraction were divided into tertiles, which were used to 
define low, moderate, and high DHA status. If data from more than one lipid fraction 
were published in the same study, DHA status was defined by using plasma 
phospholipid fatty acid data. 
We used formal inclusion/exclusion criteria and applied standard operation 
procedures for data extraction, validity assessment and meta-analysis (Hooper et al. 
2009). Meta-analysis was carried out with Cochrane software, Review Manager 
version 4.2 (Cochrane Collaboration; www.cochrane.org), with random-effects model. 
A statistically significant result indicated that the marker was indeed responding to 
supplementation. Levels of the heterogeneity were noted (heterogeneity was 
considered significant where P < 0.1 on the chi-square test or I2 > 50%). 
Because there was a danger of categorizing some biomarkers as ineffective when 
there actually was a shortage of data, such that one would not expect a statistically 
significant effect size on pooling, we would declare a biomarker effective (statistically 
significant pooled effect size; P < 0.05) or ineffective (statistically insignificant pooled 
effect size; P ≥ 0.05) only where the pooling included ≥3 studies and ≥50 participants 
overall. Where there were <3 studies or <50 participants, it was stated that there 
were insufficient data to make a decision (Hooper et al. 2009). 
 
 
4.3. Results 
4.3.1. Study inclusion 
The flow diagram of the literature search for this review is shown in Figure 7. 
Altogether 2733 titles and abstracts were identified via the electronic search, 255 of 
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them appeared to be potentially relevant, and we attempted to collect them as full-
text articles. Fifteen full articles (6%) could not be collected, but 240 full-text articles 
were available for detailed assessment for inclusion. Finally, 41 studies (divided into 
45 arms) reported in 41 publications fulfilled the inclusion criteria (Table 14). In the 
majority of cases, exclusion of articles was due to incomplete data presented; 
occasionally, an article did not describe an intervention or included nonhealthy 
subjects. 
 
 
Figure 7: Flow diagram of the systematic literature search 
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein;  
PBMC, peripheral blood mononuclear cells. 
*Number of studies reporting eicosapentaenoic acid values differs from the number reporting 
docosahexaenoic acid values. Eicosapentaenoic acid data were available as follows: 
plasma, 5 studies; plasma phospholipid, 16 studies; plasma triacylglycerol, 3 studies; 
plasma cholesteryl ester, 4 studies; plasma nonesterified fatty acid, 1 study; 
erythrocyte,5 studies; and erythrocyte phospholipid, 3 studies. 
 
  
 
 
 
Titles and abstracts that appeared 
potentially relevant, ordered as full text 
papers: 255 
Full papers not available: 15 
Titles and abstracts retrieved from 
electronic, bibliographic and expert 
searches: 2733 
Titles and abstracts very unlikely to be 
relevant: 2478 
Full papers assessed for inclusion: 240 
Papers excluded: 
Not supplementation or depletion 
studies: 14 
Non healthy subjects: 30 
Not including the micronutrient: 5 
Baseline and later status or change not 
reported: 133 
Not meeting criterion of minimal 
duration: 2 
Not determined daily intake: 5 
Imprecise data: 10 
Studies included: 
Plasma: 6* 
Plasma phospholipid: 21* 
Plasma triacylglycerol: 5* 
Plasma cholesteryl ester: 5* 
Plasma nonesterified fatty acid: 3* 
Erythrocyte: 6* 
Erythrocyte phospholipid: 6* 
Young erythrocyte ghosts: 1 
Old erythrocyte ghosts: 1 
Platelet: 8 
Granulocytes: 1 
Neutrophils: 1 
Neutrophil phospholipid: 2 
PBMC: 2 
PBMC phospholipid: 3 
LDL: 2 
HDL phospholipid: 1 
Full papers included: 41 
42 
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4.3.2. Quality of included studies 
Of the 41 studies included, 34 were parallel RCTs (83%) and 7 were B/A studies; no 
non-randomized controlled clinical trials were included (Table 14). The majority of 
studies were carried out in Europe (26 studies) and North America (10 studies). The 
studies ranged in size from 7 to 341 participants. Fourteen studies were 2–4 wk 
duration, 9 studies were 5–10 wk, 13 studies were 11–17 wk, and 5 studies were 6 
mo. The supplement was marine oil or seafood in 35 studies, single cell oil in 5, and 
DHA-rich eggs in 3 studies. The most common placebo was vegetable oil (25 
studies). The studies used a wide range of supplementation doses, from 83 mg/day 
DHA (Hoffman et al. 2004) to 4900 mg/day DHA (Kew et al. 2004). 
Aspects of methodologic quality are described in Table 15. The method of 
randomization was poorly described in the majority of studies. There were only a 
moderate number of dropouts in most of the studies, but reasons often were not 
reported. Attempts were made to assess compliance objectively in 24 studies, but the 
results of the checks, i.e. levels of compliance, were not comprehensively reported 
(in only 12 studies was there at least some attempt to describe it) (Table 15). Overall 
the risk of bias was low in only 5 studies (Allard et al. 1997; Higgins et al. 2001; 
Hoffman et al. 2004; Itomura et al. 2005; Kew et al. 2004). 
 
4.3.3. Biomarkers identified and evaluated 
Within the 41 included studies, 18 different biomarkers were used to characterize 
changes in n-3 LCPUFA status. We discuss in detail only those biomarkers that were 
used in 3 independent studies; however, the effects of n-3 LCPUFA supplementation 
on every biomarker are detailed in Table 16. In this thesis, we focus primarily on the 
effect of DHA supplementation on biomarkers reflecting changes in DHA values. 
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o
n
 
g
ro
u
p
 (
n
o
. 
o
f 
s
u
b
je
c
ts
) 
M
e
th
o
d
 f
o
r 
c
h
e
c
k
in
g
; 
R
e
s
u
lt
s
 o
f 
c
o
m
p
li
a
n
c
e
 c
h
e
c
k
 
R
is
k
 o
f 
b
ia
s
 
A
ll
a
rd
 e
t 
a
l.
 1
9
9
7
 
R
a
n
d
o
m
iz
e
d
; 
ra
n
d
o
m
 
n
u
m
b
e
r 
ta
b
le
s
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
s
id
e
 e
ff
e
c
ts
 (
2
) 
A
s
s
e
s
s
e
d
 b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
ve
ry
 g
o
o
d
 
L
o
w
 
B
o
n
a
a
 e
t 
a
l.
 1
9
9
2
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
A
b
d
o
m
in
a
l 
d
is
c
o
m
fo
rt
 (
6
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
, 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
B
ra
d
y
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
C
h
ri
s
te
n
s
e
n
 e
t 
a
l.
 1
9
9
9
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
C
le
la
n
d
 e
t 
a
l.
 1
9
9
2
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
 (
4
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
>
9
4
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
C
o
n
q
u
e
r 
a
n
d
 H
o
lu
b
 1
9
9
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
p
e
rs
o
n
a
l 
re
a
s
o
n
s
 
(3
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
, 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
C
o
n
q
u
e
r 
e
t 
a
l.
 1
9
9
9
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
 (
1
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
a
m
s
g
a
a
rd
 e
t 
a
l.
 2
0
0
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
N
/A
) 
N
/A
; 
8
8
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
e
L
a
n
y
 e
t 
a
l.
 1
9
9
0
 
R
a
n
d
o
m
iz
e
d
; 
s
tr
a
ti
fi
e
d
 b
y
 
c
h
o
le
s
te
ro
l 
le
ve
ls
 
A
p
p
e
n
d
e
c
to
m
y
 (
1
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
u
s
ta
n
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
S
ig
n
if
ic
a
n
t 
d
is
e
a
s
e
, 
n
a
u
s
e
a
 (
7
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
D
y
e
rb
e
rg
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
p
e
rs
o
n
a
l 
re
a
s
o
n
s
 
(5
) 
N
/A
; 
g
o
o
d
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
E
n
g
s
tr
ö
m
 e
t 
a
l.
 2
0
0
3
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 f
o
o
d
, 
a
s
s
e
s
s
e
d
 b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
a
g
ve
 e
t 
a
l.
 1
9
9
3
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
e
ll
a
n
d
 e
t 
a
l.
 2
0
0
6
 
R
a
n
d
o
m
iz
e
d
; 
c
o
m
p
u
te
r 
g
e
n
e
ra
te
d
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
N
/A
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
ig
g
in
s
 e
t 
a
l.
 2
0
0
1
 
R
a
n
d
o
m
iz
e
d
; 
s
tr
a
ti
fi
e
d
 b
y
 
p
la
s
m
a
 P
T
G
 l
e
ve
ls
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
 (
1
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
, 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
9
3
-9
5
%
 
L
o
w
  
H
o
d
g
e
 e
t 
a
l.
 1
9
9
3
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
H
o
ff
m
a
n
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
c
o
m
p
u
te
r 
g
e
n
e
ra
te
d
 
C
o
n
s
ti
p
a
ti
o
n
, 
re
fu
s
a
l 
to
 e
a
t 
s
o
li
d
 f
o
o
d
s
 
(3
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 f
o
o
d
; 
9
3
%
 
L
o
w
  
It
o
m
u
ra
 e
t 
a
l.
 2
0
0
5
 
R
a
n
d
o
m
iz
e
d
; 
s
tr
a
ti
fi
e
d
 b
y
 
a
g
e
, 
B
M
I 
a
n
d
 g
e
n
d
e
r 
L
o
s
t 
to
 f
o
ll
o
w
-u
p
, 
g
o
t 
c
o
ld
, 
d
id
 n
o
t 
a
g
re
e
 
fo
r 
b
lo
o
d
 s
a
m
p
lin
g
 (
6
2
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 f
o
o
d
; 
>
9
0
%
 
L
o
w
  
K
a
ta
n
 e
t 
a
l.
 1
9
9
7
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
e
xc
e
ll
e
n
t 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
K
e
w
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
s
tr
a
ti
fi
e
d
 b
y
 
a
g
e
, 
B
M
I 
a
n
d
 P
T
G
 l
e
ve
ls
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
>
9
0
%
 
L
o
w
 
K
h
a
n
 e
t 
a
l.
 2
0
0
3
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 i
n
fo
rm
a
ti
o
n
 o
n
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 s
u
p
p
le
m
e
n
t,
 a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
g
e
n
e
ra
lly
 g
o
o
d
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
L
a
id
la
w
 a
n
d
 H
o
lu
b
 2
0
0
3
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
A
s
s
e
s
s
e
d
 b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
 
46 
 
 
 T
a
b
le
 1
5
. 
(C
o
n
ti
n
u
e
d
) 
S
tu
d
ie
s
 
R
a
n
d
o
m
iz
e
d
?
 
M
e
th
o
d
 o
f 
ra
n
d
o
m
iz
a
ti
o
n
 
R
e
a
s
o
n
s
 f
o
r 
d
ro
p
o
u
ts
 b
y
 
in
te
rv
e
n
ti
o
n
 g
ro
u
p
 (
n
o
. 
o
f 
s
u
b
je
c
ts
) 
M
e
th
o
d
 f
o
r 
c
h
e
c
k
in
g
; 
R
e
s
u
lt
s
 o
f 
c
o
m
p
li
a
n
c
e
 c
h
e
c
k
 
R
is
k
 o
f 
b
ia
s
 
M
a
n
tz
io
ri
s
 e
t 
a
l.
 1
9
9
4
 
N
o
n
-r
a
n
d
o
m
iz
e
d
 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
M
il
e
s
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
N
/A
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
M
ill
s
 e
t 
a
l.
 1
9
9
5
  
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
 n
o
t 
re
p
o
rt
e
d
 (
1
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
M
o
n
tg
o
m
e
ry
 e
t 
a
l.
 2
0
0
3
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
n
a
u
s
e
a
 
g
ra
vi
d
a
ru
m
, 
lo
s
s
 o
f 
c
o
n
ta
c
t 
(1
9
) 
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
O
tt
o
 e
t 
a
l.
 2
0
0
0
* 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
s
id
e
 e
ff
e
c
ts
, 
m
o
vi
n
g
 a
w
a
y
 (
4
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
O
tt
o
 e
t 
a
l.
 2
0
0
0
**
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
a
lo
z
z
a
 e
t 
a
l.
 1
9
9
6
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
P
a
rk
 a
n
d
 H
a
rr
is
 2
0
0
2
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
2
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
R
e
e
s
 e
t 
a
l.
 2
0
0
6
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
L
a
c
k
 o
f 
c
o
m
p
li
a
n
c
e
, 
in
c
o
n
ve
n
ie
n
c
e
, 
c
a
r 
a
c
c
id
e
n
t,
 m
y
o
c
a
rd
ia
l 
in
fa
rc
ti
o
n
, 
d
ia
rr
h
e
a
, 
c
o
n
s
ti
p
a
ti
o
n
 (
N
/A
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
a
n
d
e
rs
 e
t 
a
l.
 2
0
0
6
 
R
a
n
d
o
m
iz
e
d
; 
s
tr
a
ti
fi
e
d
 b
y
 
g
e
n
d
e
r 
N
o
 d
ro
p
o
u
ts
 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 c
a
p
s
u
le
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
a
n
ju
rj
o
 e
t 
a
l.
 2
0
0
4
 
R
a
n
d
o
m
iz
e
d
; 
c
o
m
p
u
te
r 
g
e
n
e
ra
te
d
 n
u
m
b
e
r 
ta
b
le
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
2
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
m
u
ts
 e
t 
a
l.
 2
0
0
3
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
9
) 
C
o
u
n
t 
o
f 
re
tu
rn
e
d
 e
g
g
s
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
o
re
n
s
e
n
 e
t 
a
l.
 1
9
9
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
2
) 
R
e
c
o
rd
s
 o
f 
m
a
rg
a
ri
n
e
 u
s
e
, 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
1
0
0
%
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
ta
rk
 e
t 
a
l.
 2
0
0
0
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
S
u
ra
i 
e
t 
a
l.
 2
0
0
0
 
R
a
n
d
o
m
iz
e
d
; 
s
tr
a
ti
fi
e
d
 b
y
 
a
g
e
 a
n
d
 g
e
n
d
e
r 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
2
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
T
h
ie
s
 e
t 
a
l.
 2
0
0
1
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
S
to
m
a
c
h
 u
p
s
e
t 
(1
) 
S
e
lf
-r
e
p
o
rt
in
g
 q
u
e
s
ti
o
n
n
a
ir
e
, 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
V
o
g
n
ild
 e
t 
a
l.
 1
9
9
8
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
R
e
a
s
o
n
s
 n
o
t 
re
p
o
rt
e
d
 (
N
/A
) 
N
/A
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
W
a
ll
a
c
e
 e
t 
a
l.
 2
0
0
0
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
V
e
rb
a
ll
y
 a
s
s
e
s
s
e
d
; 
s
a
ti
s
fa
c
to
ry
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
Y
a
q
o
o
b
 e
t 
a
l.
 2
0
0
0
 
R
a
n
d
o
m
iz
e
d
; 
N
/A
 
N
o
 d
ro
p
o
u
ts
 
S
e
lf
-r
e
p
o
rt
in
g
 q
u
e
s
ti
o
n
n
a
ir
e
, 
a
s
s
e
s
s
e
d
 
b
io
c
h
e
m
ic
a
l 
p
a
ra
m
e
te
rs
; 
N
/A
 
M
o
d
e
ra
te
 o
r 
h
ig
h
 
A
b
b
re
vi
a
ti
o
n
s
: 
N
/A
, 
n
o
 a
va
ila
b
le
 d
a
ta
; 
B
M
I,
 b
o
d
y 
m
a
s
s
 in
d
e
x;
 P
T
G
, 
p
la
sm
a
 t
ri
a
c
yl
g
ly
c
e
ro
l.
 
*,
 O
tt
o
 e
t 
a
l.
 N
u
tr
 R
e
s
 2
0
0
0
; 
**
, 
O
tt
o
 e
t 
a
l.
 P
ro
s
ta
g
la
n
d
in
s 
L
e
u
k
o
t 
E
s
s
e
n
t 
F
a
tt
y 
A
c
id
s
 2
0
0
0
. 
L
o
w
 r
is
k
 o
f 
b
ia
s
 m
e
a
n
t 
th
a
t 
th
e
 s
tu
d
y
 w
a
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Table 16: Primary analyses (the longest duration and the highest supplementation 
dose) for each of the identified biomarkers for supplementation with n-3 long-chain 
polyunsaturated fatty acids 
Abbreviations: MD, mean difference; CI, confidence interval; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; N/A, no available data; PBMC, peripheral blood mononuclear cell; LDL, low-
density lipoprotein; HDL, high-density lipoprotein. 
1
, all studies are in %DHA of total fatty acids unless otherwise stated; 
2
, %EPA of total fatty acid; 
3
, 
μg/mg protein. 
To claim that a biomarker was effective (reflected change in status) within a review, 3 conditions needed to be 
meet: 1) statistical significance within a forest plot (95% CI did not include 0 or P <0.05), 2) ≥3 trials contributing 
data, and 3) ≥50 participants contributing data in the intervention and control arm. To claim that a biomarker was 
ineffective, 4 conditions had to be met: 1) lack of statistical significance within a forest plot (95% CI included 0 or 
P ≥0.05); 2) ≥3 trials contributing data; 3) ≥50 participants contributing data in the intervention and control arm. 
 
4.3.3.1. Total plasma lipid DHA 
Six RCTs contained eligible data on the effect of DHA supplementation on the 
percentage contribution of DHA to the fatty acid composition of total plasma lipids. 
The primary analysis, to assess whether the biomarker was responding to change in 
DHA status, of the largest dose and longest duration of supplementation within each 
publication showed a statistically significant increase in each study and also in the 
pooled response (MD: 1.13% DHA; 95% CI: 0.54, 1.71; 262 participants; I2 = 89%). 
This suggested that total plasma lipid DHA is an effective biomarker of DHA status 
(Table 16). However, the high level of heterogeneity in this primary analysis means 
that the biomarker responded differently in the included studies; the reasons for 
these differences were explored through subgrouping of studies by their different 
characteristics. 
When the data were subgrouped according to dose of supplementation (Figure 8), 
even the lowest-dose category (<300 mg DHA/day) showed a statistically significant 
Biomarker 
No. of studies 
(no. of included 
participants) 
Pooled effect size, 
MD (95% CI)
1 
Heterogeneity 
I
2
 (%) 
Appears 
effective as a 
biomarker? 
Plasma DHA 6 (262) 1.13 [0.54, 1.71] 88.7 Yes 
Plasma phospholipid DHA 21 (923) 2.45 [1.87, 3.02] 94.0 Yes 
Plasma phospholipid EPA 16 (759) 4.07 [2.90, 5.24]
2 
99.0 Yes 
Plasma triacylglycerol DHA 5 (116) 0.86 [0.08, 1.65] 92.1 Yes 
Plasma cholesteryl ester DHA 5 (110) 0.42 [0.13, 0.71] 92.2 Yes 
Plasma nonesterified DHA 3 (72) 1.35 [0.11, 2.59] 95.0 Yes 
Erythrocyte DHA 6 (277) 2.33 [0.86, 3.81] 94.0 Yes 
Erythrocyte phospholipid DHA 6 (229) 0.97 [0.50, 1.43] 72.3 Yes 
Young erythrocyte ghosts DHA 1 (17) -1.00 [-4.07, 2.07]
3 
N/A Unclear 
Old erythrocyte ghosts DHA 1 (17) 1.70 [0.32, 3.08]
3 
N/A Unclear 
Platelet DHA 8 (235) 1.25 [0.87, 1.64] 79.9 Yes 
Granulocyte DHA 1 (40) 0.60 [0.32, 0.88] N/A Unclear 
Neutrophil DHA 1 (20) 2.80 [0.01, 5.59] N/A Unclear 
Neutrophil phospholipid DHA 2 (28) 0.04 [-0.15, 0.23] N/A Unclear 
PBMC DHA 2 (36) 0.06 [-0.36, 0.48] 0 Unclear 
PBMC phospholipid DHA 3 (94) 0.70 [-0.66, 2.06] 93.9 No 
LDL DHA 2 (73) 0.60 [0.59, 0.61] 0 Unclear 
HDL phospholipid DHA 1 (7) 0.80 [0.07, 1.53] N/A Unclear 
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effect (P = 0.0007) over 14–25wk. There appeared to be an almost linear increase in 
total plasma DHA values with increasing supplementation dose: the percentage of 
DHA in plasma lipids was >8-fold higher when supplementing with DHA doses >2500 
mg DHA/day was compared with doses <300 mg DHA/day (comparison of subgroup 
MD, Figure 8). Total plasma DHA appeared to usefully reflect changed DHA status in 
studies of adults, mixed sex studies (same results as for adult studies), those with 
moderate baseline plasma DHA status, those supplemented with marine oil or 
seafood, and all those whose doses were ≤2500 mg DHA/day. (Table 17 and Figure 
8). Although there were several subgroups for which there were insufficient studies to 
be clear about how effective the biomarker was in that subgroup, there were no 
subgroups for which total plasma DHA clearly did not reflect changes in DHA status. 
Table 17: Subgroup analysis of the results of the systematic review of data on 
changes in total plasma docosahexaenoic acid (DHA) to supplementation with DHA 
 
Abbreviations: RCT, randomized controlled trial; B/A, before-after study; MD, mean difference; CI, 
confidence interval; N/A, no available data. 
1
, Data were divided into tertiles to define low, moderate and high baseline status. If data for more than 
one lipid fraction were published in the same study, plasma phospholipid fatty acid data were used to 
define DHA baseline status. 
To claim that a biomarker was effective (reflected change in status) within a review, 3 conditions needed to be 
met: 1) statistical significance within a forest plot (95% CI did not include 0 or P <0.05), 2) ≥3 trials contributing 
data, and 3) ≥50 participants contributing data in the intervention and control arm. To claim that a biomarker was 
ineffective, 3 conditions had to be met: 1) lack of statistical significance within a forest plot (95% CI included 0 or 
P ≥0.05); 2) ≥3 trials contributing data; 3) ≥50 participants contributing data in the intervention and control arm. 
  
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity
I
2
 
Biomarker 
useful? RCTs B/A 
 % of total fatty acid no. of studies (no. of participants) %  
All studies (primary outcome) 1.13 [0.54, 1.71] 6 (262) N/A 88.7 Yes 
Pregnancy and lactation 0.34 [0.16, 0.53] 2 (75) N/A 0 Unclear 
Adults 1.72 [0.80, 2.64] 4 (187) N/A 81.6 Yes 
Mixed 1.72 [0.80, 2.64] 4 (187) N/A 81.6 Yes 
Females 0.34 [0.16, 0.53] 2 (75) N/A 0 Unclear 
Low status at baseline
1 
0.37 [0.10, 0.65] 2 (87) N/A 13.8 Unclear 
Moderate status at baseline
1 
2.12 [1.22, 3.03] 3 (159) N/A 64.0 Yes 
High status at baseline
1 
0.40 [0.12, 0.68] 1 (16) N/A N/A Unclear 
Marine oil or seafood 0.79 [0.31, 1.26] 5 (183) N/A 81.6 Yes 
Single cell oil 2.66 [1.78, 3.54] 1 (79) N/A N/A Unclear 
<300 mg DHA/day 0.30 [0.13, 0.48] 3 (122) N/A 0 Yes 
300 to 1500 mg DHA/day 0.62 [0.30, 0.95] 3 (185) N/A 0 Yes 
1500 to 2500 mg DHA/day 1.85 [1.01, 2.70] 3 (195) N/A 64.7 Yes 
>2500 mg DHA/day 2.60 [0.92, 4.28] 1 (20) N/A N/A Unclear 
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Figure 8: Response of total plasma docosahexaenoic acid (DHA) to supplementation 
with DHA [%DHA/total fatty acid composition (weight/weight)] 
Specification of the groups as represented in the original articles: A, combined data of 0.3-g n-3 
polyunsaturated fatty acid (PUFA) and 0.6-g n-3 PUFA groups; B, 0.9-g n-3 PUFA group; C, 2.5-g n-3 
PUFA group; D, 5.1-g n-3 PUFA group; E, 7.7-g n-3 PUFA group; F, combined data of refined whale 
oil, crude whale oil, and olive oil/cod liver oil groups; and G, combined data of cod liver oil and seal 
oil/cod liver oil groups. 
 
4.3.3.2. Plasma phospholipid DHA 
Information on plasma phospholipid DHA was available for 21 studies (17 RCTs and 
4 B/A studies). The primary analysis showed a highly significant increase of 
percentage DHA in plasma phospholipids (MD: 2.45% DHA; 95% CI: 1.87, 3.02; 21 
studies; 923 participants; I2 = 94%) but with high levels of heterogeneity (Table 16). 
There were sufficient studies and participants and a sufficiently statistically significant 
effect on plasma phospholipid DHA to declare the biomarker effective in the following 
subgroups: adults; males; mixed sexes; females; those with low, moderate, or high 
baseline DHA status; those who used either marine oil, seafood, or single cell oils; 
Study or Subgroup
1.1.1 <300 mg DHA/day
Higgins et al. 2001 A
Montgomery et al. 2003
Sanjurjo et al. 2004
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.78, df = 2 (P = 0.41); I² = 0%
Test for overall effect: Z = 3.40 (P = 0.0007)
1.1.2 300 to 1500 mg DHA/day
Higgins et al. 2001 B
Palozza et al. 1996 C
Vognild et al. 1998 F
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.42, df = 2 (P = 0.81); I² = 0%
Test for overall effect: Z = 3.78 (P = 0.0002)
1.1.3 1500 to 2500 mg DHA/day
Palozza et al. 1996 D
Sanders et al. 2006
Vognild et al. 1998 G
Subtotal (95% CI)
Heterogeneity: Tau² = 0.35; Chi² = 5.67, df = 2 (P = 0.06); I² = 65%
Test for overall effect: Z = 4.31 (P < 0.0001)
1.1.4 >2500 mg DHA/day
Palozza et al. 1996 E
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.03 (P = 0.002)
Mean
2.13
1.4
3.17
2.76
3.5
3.27
3.8
5.45
4.2
5.1
SD
0.42
0.56
0.26
0.69
1.27
0.59
1.9
2.38
0.78
2.21
Total
33
30
8
71
14
10
102
126
10
40
61
111
10
10
Mean
2.11
1.1
2.77
2.11
2.5
2.7
2.5
2.79
2.7
2.5
SD
0.88
0.41
0.31
0.88
1.58
1.18
1.58
1.51
1.18
1.58
Total
14
29
8
51
14
10
35
59
10
39
35
84
10
10
Weight
13.0%
48.5%
38.5%
100.0%
30.4%
6.6%
62.9%
100.0%
19.4%
33.9%
46.7%
100.0%
100.0%
100.0%
IV, Random, 95% CI
0.02 [-0.46, 0.50]
0.30 [0.05, 0.55]
0.40 [0.12, 0.68]
0.30 [0.13, 0.48]
0.65 [0.06, 1.24]
1.00 [-0.26, 2.26]
0.57 [0.16, 0.98]
0.62 [0.30, 0.95]
1.30 [-0.23, 2.83]
2.66 [1.78, 3.54]
1.50 [1.06, 1.94]
1.85 [1.01, 2.70]
2.60 [0.92, 4.28]
2.60 [0.92, 4.28]
Supplementation Control Mean Difference Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Intervention lower Intervention higher
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and those who had dose levels ≤2500 mg DHA/day. Although the response appeared 
to increase with increasing doses of DHA ≤2500 mg/day, additional dose increases 
did not appear to alter plasma phospholipid DHA further (Table 18 and Figure 9). 
The effect was not significant in pregnancy and lactation. There were insufficient data 
to assess whether it was a good biomarker in all other groups. Overall, plasma 
phospholipid DHA appears to be a good biomarker of DHA status, which reacts 
rapidly to supplementation and is sensitive to supplementation dose. 
Table 18: Subgroup analysis of the results of the systematic review of data on 
changes in plasma phospholipid docosahexaenoic acid (DHA) to supplementation 
with DHA 
 
See details below Table 17. 
4.3.3.3. Plasma phospholipid EPA 
In addition to the evaluation of DHA biomarkers in response to DHA intake, we also 
examined the response of plasma phospholipid EPA to dietary supplementation with 
EPA. Data on plasma phospholipid EPA were available from 16 studies (12 RCTs 
and 4 B/A studies). Primary analysis of the largest dose and longest duration of 
intervention showed significant increase of plasma phospholipid EPA (MD: 4.07% 
EPA; 95% CI: 2.90, 5.24; 16 studies; 759 participants; I2 = 99%). 
 
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity
I
2
 
Biomarker 
useful? RCTs B/A 
 % of total fatty acid no. of studies (no. of participants) %  
All studies (primary outcome) 2.45 [1.87, 3.02] 17 (885) 4 (38) 94.0 Yes 
Pregnancy and lactation 1.44 [-0.01, 2.89] 3 (367) N/A 95.0 No 
Adults 2.47 [1.79, 3.16] 11 (439) 4 (38) 93.5 Yes 
Post-menopausal women 3.10 [2.39, 3.81] 1 (35) N/A N/A Unclear 
The elderly 0.70 [-0.56, 1.96] 1 (31) N/A N/A Unclear 
Low income and immigrants 6.30 [5.29, 7.31] 1 (13) N/A N/A Unclear 
Males 2.72 [1.51, 3.94] 6 (163) 1 (15) 96.6 Yes 
Mixed 2.57 [1.07, 4.07] 6 (293) 1 (8) 93.9 Yes 
Females 2.09 [1.40, 2.78] 5 (429) 2 (15) 89.1 Yes 
Low status at baseline 2.57 [1.89, 3.26] 5 (120) N/A 60.0 Yes 
Moderate status at baseline 2.64 [1.67, 3.60] 8 (257) 3 (30) 96.7 Yes 
High status at baseline 1.93 [1.24, 2.63] 4 (508) 1 (8) 73.8 Yes 
Marine oil or seafood 2.59 [1.99, 3.18] 12 (747) 4 (38) 92.2 Yes 
Single cell oil 3.16 [0.56, 5.77] 3 (64) N/A 97.0 Yes 
DHA-rich egg 0.56 [0.16, 0.97] 2 (74) N/A 0 Unclear 
<300 mg DHA/day 0.85 [0.62, 1.09] 4 (138) 1 (8) 7.1 Yes 
300 to 1500 mg DHA/day 1.99 [1.40, 2.58] 11 (686) 3 (30) 91.6 Yes 
1500 to 2500 mg DHA/day 3.83 [2.78, 4.87] 5 (250) 1 (8) 92.6 Yes 
>2500 mg DHA/day 2.74 [2.03, 3.44] 2 (31) N/A 0 Unclear 
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Figure 9: Response of plasma phospholipid docosahexaenoic acid (DHA) to 
supplementation with DHA [%DHA/total fatty acid composition (weight/weight)] 
Specification of the groups as represented in the original articles: A, DHA group; B, eicosapentaenoic 
acid group; C, 20-g fish oil group; D, 5-g fish oil group; E, ordinary caviar paste group; F, fish oil–
enriched caviar paste group; G, combined data of low fish oil and low DHA groups; H, combined data 
of high fish oil and high DHA groups; I, blend 3 group; J, combined data of eicosapentaenoic acid, 
blend 1, and blend 2 groups; K, high DHA group; L, low DHA group; and M, combined data of low, 
moderate, and high groups. 1 indicates the older group within the study, and 2, the younger group 
within the study. 
*, Otto et al. Nutr Res 2000.; **, Otto et al. Prostaglandins Leukot Essent Fatty Acids 2000. 
Study or Subgroup
1.2.1 < 300 mg DHA/day
Engström et al. 2003 E
Miles et al. 2004 I
Otto et al. 2000 * G
Smuts et al. 2003
Surai et al. 2000
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 4.31, df = 4 (P = 0.37); I² = 7%
Test for overall effect: Z = 7.12 (P < 0.00001)
1.2.2 300 to 1500 mg DHA/day
Conquer & Holub 1998 L
DeLany et al. 1990 D
Engström et al. 2003 F
Helland et al. 2006
Hodge et al. 1993
Kew, 2004 () B
Khan et al. 2003
Mantzioris et al. 1994
Miles et al. 2004 J
Otto et al. 2000 * H
Otto et al. 2000 **
Rees et al. 2006 1M
Rees et al. 2006 2M
Yaqoob et al. 2000
Subtotal (95% CI)
Heterogeneity: Tau² = 0.99; Chi² = 155.17, df = 13 (P < 0.00001); I² = 92%
Test for overall effect: Z = 6.59 (P < 0.00001)
1.2.3 1500 to 2500 mg DHA/day
Allard et al. 1997
Bønaa et al. 1992
Conquer & Holub 1998 K
Conquer et al. 1999
Laidlaw & Holub 2003
Stark et al. 2000
Subtotal (95% CI)
Heterogeneity: Tau² = 1.56; Chi² = 67.43, df = 5 (P < 0.00001); I² = 93%
Test for overall effect: Z = 7.19 (P < 0.00001)
1.2.4 >2500 mg DHA/day
DeLany et al. 1990 C
Kew et al. 2004 A
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.00, df = 1 (P = 0.32); I² = 0%
Test for overall effect: Z = 7.62 (P < 0.00001)
Mean
4.6
4.2
4.24
3.73
4.9
8
2.8
5.6
8.27
5.5
7.6
4.6
7.6
4.27
5.09
5.97
5.73
4.37
4.9
8.11
10.1
9.9
6.4
6.37
6.4
4
13.5
SD
0.5
0.95
0.83
1.08
0.89
0.9
0.45
0.9
1.92
1.7
3.65
2.12
1
1.15
0.79
1.18
1.51
0.74
3.39
1.1
1.8
1.2
1.2
0.62
0.85
0.6
10.28
Total
8
10
29
18
20
85
6
5
8
158
7
11
28
15
30
27
12
46
69
8
430
18
72
7
9
8
18
132
4
11
15
Mean
3.7
2.9
3.27
3.32
4.2
3.6
1.3
4.3
5.78
3
7.3
2.13
3.7
2.9
3.27
4.6
5.1
3.4
4
3.32
7.7
3.6
2.8
3.41
3.3
1.3
7.3
SD
0.2
0.63
0.7
0.64
0.89
0.6
0.45
0.7
0.34
0.9
5.31
1.72
0.6
0.63
0.7
1.07
2
0.49
3.11
0.44
1.8
0.6
0.63
0.71
1.24
0.45
5.31
Total
8
10
15
16
20
69
6
5
8
151
7
11
28
15
10
15
12
16
24
8
316
19
74
6
10
8
17
134
5
11
16
Weight
34.4%
10.6%
23.2%
14.9%
16.9%
100.0%
7.7%
8.5%
7.9%
9.0%
6.0%
1.9%
7.2%
8.4%
8.5%
8.7%
7.6%
7.1%
9.0%
2.5%
100.0%
17.3%
17.2%
15.5%
16.1%
17.0%
16.8%
100.0%
98.9%
1.1%
100.0%
IV, Random, 95% CI
0.90 [0.53, 1.27]
1.30 [0.59, 2.01]
0.97 [0.50, 1.44]
0.41 [-0.18, 1.00]
0.70 [0.15, 1.25]
0.85 [0.62, 1.09]
4.40 [3.53, 5.27]
1.50 [0.94, 2.06]
1.30 [0.51, 2.09]
2.49 [2.19, 2.79]
2.50 [1.08, 3.92]
0.30 [-3.51, 4.11]
2.47 [1.46, 3.48]
3.90 [3.31, 4.49]
1.37 [0.80, 1.94]
1.82 [1.36, 2.28]
1.37 [0.47, 2.27]
0.63 [-0.44, 1.70]
0.97 [0.71, 1.23]
0.90 [-2.29, 4.09]
1.99 [1.40, 2.58]
4.79 [4.24, 5.34]
2.40 [1.82, 2.98]
6.30 [5.29, 7.31]
3.60 [2.72, 4.48]
2.96 [2.31, 3.61]
3.10 [2.39, 3.81]
3.83 [2.78, 4.87]
2.70 [1.99, 3.41]
6.20 [-0.64, 13.04]
2.74 [2.03, 3.44]
Supplementation Control Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Intervention lower Intervention higher
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There was evidence that phospholipid EPA was an effective biomarker of EPA status 
in adults; males; females; mixed sex populations; those with low, moderate, or high 
baseline EPA status; and those given marine oil or seafood (Table 19). Subgroup 
analyses showed significant effects in all dose categories, and increased response 
with increased dose (although this did not decrease heterogeneity between studies a 
great deal) (Figure 10). No subgroups suggested that plasma phospholipid EPA was 
not an effective biomarker of EPA status, but there were insufficient studies to assess 
this in some groups. Overall, plasma phospholipid EPA appears to be a good 
biomarker of EPA status. 
Table 19: Subgroup analysis of the results of the systematic review of data on 
changes in plasma phospholipid EPA to supplementation with EPA 
 
See details below Table 17. 
  
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity
I
2
 
Biomarker 
useful? RCTs B/A 
 % of total fatty acid no. of studies (no. of participants) %  
All studies (primary outcome) 4.07 [2.90, 5.24] 12 (721) 4 (38) 99.3 Yes 
Pregnancy and lactation 1.69 [1.52, 1.86] 1 (309) N/A N/A Unclear 
Adults 3.88 [2.57, 5.19] 9 (346) 4 (38) 98.7 Yes 
Post-menopausal women 5.68 [5.43, 5.93] 1 (35) N/A N/A Unclear 
The elderly 7.20 [6.22, 8.18] 1 (31) N/A N/A Unclear 
Males 5.08 [3.80, 6.35] 6 (163) 1 (15) 91.8 Yes 
Mixed 3.77 [0.48, 7.07] 3 (184) 1 (8) 98.0 Yes 
Females 2.96 [1.04, 4.88] 3 (374) 2 (15) 99.8 Yes 
Low status at baseline 3.61 [2.33, 4.89] 4 (64) N/A 78.7 Yes 
Moderate status at baseline 4.26, [1.97, 6.55] 4 (149) 3 (30) 99.7 Yes 
High status at baseline 4.25 [2.12, 6.37] 4 (508) 1 (8) 98.6 Yes 
Marine oil or seafood 4.07 [2.90, 5.24] 12 (721) 4 (38) 99.3 Yes 
<300 mg EPA/day 0.36 [0.19, 0.54] 1 (45) 1 (8) 0 Unclear 
300 to 1500 mg EPA/day 2.01 [1.61, 2.42] 7 (479) 2 (15) 82.1 Yes 
1500 to 2500 mg EPA/day 4.08 [2.77, 5.38] 3 (71) 2 (23) 92.2 Yes 
>2500 mg EPA/day 5.92 [4.95, 6,89] 6 (330) N/A 98.8 Yes 
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Figure 10: Response of plasma phospholipid eicosapentaenoic acid (EPA) to 
supplementation with EPA [%EPA/total fatty acid composition (weight/weight)] 
Specification of the groups as represented in the original articles: A, docosahexaenoic acid (DHA) 
group; B, EPA group; C, 20-g fish oil group; D, 5-g fish oil group; E, ordinary caviar paste group; F, fish 
oil–enriched caviar paste group; G, combined data of low fish oil and high fish oil groups; H, combined 
data of blend 1, blend 2, and blend 3 groups; I, EPA group; J, combined data of moderate EPA and 
high EPA groups; and K, low EPA group. 1 indicates the older group within the study, and 2, the 
younger group within the study. 
 
4.3.3.4. Plasma triacylglycerol DHA 
There were 5 studies of changes of plasma triacylglycerol DHA values in response to 
DHA supplementation (3 RCTs and 2 B/A studies). The pooled response in the 
Study or Subgroup
1.3.1 < 300 mg EPA/day
Engström et al. 2003 E
Otto et al. 2000 * G
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.99, df = 1 (P = 0.32); I² = 0%
Test for overall effect: Z = 4.10 (P < 0.0001)
1.3.2 300 to 1500 mg EPA/day
Conquer et al. 1999
DeLany et al. 1990 D
Engström et al. 2003 F
Helland et al. 2006
Hodge et al. 1993
Kew et al. 2004 A
Miles et al. 2004 H
Rees et al. 2006 1K
Rees et al. 2006 2K
Subtotal (95% CI)
Heterogeneity: Tau² = 0.25; Chi² = 44.65, df = 8 (P < 0.00001); I² = 82%
Test for overall effect: Z = 9.83 (P < 0.00001)
1.3.3 1500 to 2500 mg EPA/day
Laidlaw & Holub 2003
Mantzioris et al. 1994
Miles et al. 2004 I
Stark et al. 2000
Yaqoob et al. 2000
Subtotal (95% CI)
Heterogeneity: Tau² = 1.90; Chi² = 51.34, df = 4 (P < 0.00001); I² = 92%
Test for overall effect: Z = 6.13 (P < 0.00001)
1.3.4 >2500 mg EPA/day
Allard et al. 1997
Bønaa et al. 1992
DeLany et al. 1990 C
Kew, 2004 () B
Rees et al. 2006 1J
Rees et al. 2006 2J
Subtotal (95% CI)
Heterogeneity: Tau² = 1.10; Chi² = 32.04, df = 5 (P < 0.00001); I² = 84%
Test for overall effect: Z = 11.99 (P < 0.00001)
Mean
1.8
0.82
4.6
2.3
2.4
2.33
2.6
4.5
2.43
5.2
3
6.36
4.4
4.1
6.44
3.6
8.85
8.5
5.4
7.2
8.2
5.5
SD
0.6
0.47
1.53
0.67
0.6
1
0.3
4.31
1.1
1.2
0.96
1.47
1.4
1.9
0.42
2.26
2.38
2.5
0.6
6.3
1.77
2.23
Total
8
30
38
9
5
8
158
7
11
30
16
23
267
8
15
10
18
8
59
18
72
4
11
30
46
181
Mean
1.2
0.49
0.78
0.3
1.2
0.64
0.6
1.3
1.5
1.9
1
1.12
0.6
1.5
0.76
1.2
0.99
2.4
0.3
1.3
1.9
1
SD
0.4
0.15
0.38
0.67
0.3
0.38
0.3
2.32
0.95
1.2
0.49
0.37
0.2
0.95
0.33
1.41
0.35
1.3
0.67
2.32
1.2
0.49
Total
8
15
23
10
5
8
151
7
11
10
16
24
242
8
15
10
17
8
58
19
74
5
11
16
24
149
Weight
12.0%
88.0%
100.0%
8.0%
9.8%
13.8%
16.4%
15.3%
1.7%
11.1%
9.8%
14.1%
100.0%
20.3%
21.8%
18.9%
23.1%
15.9%
100.0%
17.2%
20.2%
19.1%
4.7%
18.9%
20.0%
100.0%
IV, Random, 95% CI
0.60 [0.10, 1.10]
0.33 [0.15, 0.51]
0.36 [0.19, 0.54]
3.82 [2.79, 4.85]
2.00 [1.17, 2.83]
1.20 [0.74, 1.66]
1.69 [1.52, 1.86]
2.00 [1.69, 2.31]
3.20 [0.31, 6.09]
0.93 [0.22, 1.64]
3.30 [2.47, 4.13]
2.00 [1.56, 2.44]
2.01 [1.61, 2.42]
5.24 [4.19, 6.29]
3.80 [3.08, 4.52]
2.60 [1.28, 3.92]
5.68 [5.43, 5.93]
2.40 [0.55, 4.25]
4.08 [2.77, 5.38]
7.86 [6.75, 8.97]
6.10 [5.45, 6.75]
5.10 [4.27, 5.93]
5.90 [1.93, 9.87]
6.30 [5.44, 7.16]
4.50 [3.83, 5.17]
5.92 [4.95, 6.89]
Supplementation Control Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Intervention lower Intervention higher
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primary analysis of the largest dose and longest duration showed significant increase 
(MD: 0.86% DHA; 95% CI: 0.08, 1.65; 5 studies; 116 participants; I2 = 92%) but with 
significant heterogeneity (Table 16). There were too few studies to explore the 
causes of heterogeneity with subgrouping. Plasma triacylglycerol DHA may be a 
good biomarker of DHA status, but there were insufficient studies to allow exploration 
of which population groups it may be most effective. 
 
4.3.3.5. Plasma cholesteryl ester DHA 
Response of plasma cholesteryl ester DHA values to DHA supplementation was 
reported in 5 studies (3 RCTs and 2 B/A studies). Primary analysis showed a 
significant increase of plasma cholesteryl ester DHA values on DHA supplementation 
(MD: 0.42% DHA; 95% CI: 0.13, 0.71; 5 studies; 110 participants; I2 = 92%) with 
significant heterogeneity (Table 16). Although there were no data for the >2500 or 
1500–2500 mg DHA/day dose categories, we observed significant increases in the 
lower dose categories. There were insufficient studies for further subgrouping. 
Plasma cholesteryl ester DHA appears to be a good biomarker of DHA status at 
lower-dose supplementation, but it is not clear within which population groups it is 
effective or whether it works well at higher doses of supplementation. 
 
4.3.3.6. Plasma nonesterified fatty acid DHA 
Three RCTs assessed the contribution of DHA to plasma nonesterified fatty acids 
after DHA supplementation in adults. The primary analysis evaluating the largest 
dose and longest duration suggested a statistically significant response of plasma 
nonesterified fatty acid DHA (MD: 1.35% DHA; 95% CI: 0.11, 2.59; 3 studies; 72 
participants; I2 = 95%) (Table 16). There were insufficient studies to perform 
subgroup analysis. Plasma nonesterified fatty acid DHA may be a good biomarker of 
DHA status, but there were insufficient studies to allow exploration of 
appropriateness of its use for different population groups and doses. 
 
4.3.3.7. Erythrocyte membrane total lipid DHA 
Changes in the contribution of DHA to total erythrocyte membrane lipids on DHA 
supplementation were examined in 6 RCTs. The primary analysis showed a 
statistically significant increase (MD: 2.33% DHA; 95% CI: 0.86, 3.81; 6 studies; 277 
participants; I2 = 94%) with significant heterogeneity (Table 16). There were 2 RCTs 
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each in infants, pregnant or lactating women, and adults, so there were insufficient 
studies to be sure whether erythrocyte DHA was a good marker of DHA status in any 
single group. There was evidence that erythrocyte DHA was a good marker for 
studies of mixed sex groups with moderate baseline DHA status and those 
supplemented with marine oil or seafood and/or given 300–1500 mg DHA/day (Table 
20). Inclusion of every dose of supplementation resulted in 9 substudies (Figure 11). 
Although the number of studies was insufficient to assess biomarker effectiveness in 
studies providing >1500 mg DHA/day, and the effect was not statistically significant 
(P = 0.09) in the lowest dose (<300 mg DHA/day), the forest plot suggested that 
erythrocyte membrane lipid DHA rose with supplementation dose. Erythrocyte 
membrane total lipid DHA appears to be a good biomarker of DHA status, and the 
data suggest that there is a dose response, which may explain some of the 
heterogeneity in the primary analysis. Although it appears to be an effective 
biomarker in infants for most doses, confirmation is not possible due to limited data. 
 
Table 20: Subgroup analysis of the results of the systematic review of data on 
changes in total erythrocyte docosahexaenoic acid (DHA) to supplementation with 
DHA 
 
See details below Table 17. 
  
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity
I
2
 
Biomarker 
useful? RCTs B/A 
 % of total fatty acid no. of studies (no. of participants) %  
All studies (primary outcome) 2.33 [0.86, 3.81] 6 (277) N/A 94.0 Yes 
Infants 2.40 [1.82, 2.98] 2 (99) N/A 0 Unclear 
Pregnancy and lactation 2.55 [-1.07, 6.18] 2 (130) N/A 98.7 Unclear 
Adults 1.98 [-1.34, 5.31] 2 (48) N/A 77.7 Unclear 
Males 0.40 [-1.45, 2.25] 1 (28) N/A N/A Unclear 
Mixed 2.47 [1.91, 3.04] 3 (119) N/A 0 Yes 
Females 2.55 [-1.07, 6.18] 2 (130) N/A 98.7 Unclear 
Low status at baseline 0.70 [0.08, 1.32] 1 (57) N/A N/A Unclear 
Moderate status at baseline 2.14 [0.54, 3.75] 3 (99) N/A 64.4 Yes 
High status at baseline 3.37 [1.32, 5.43] 2 (121) N/A 94.1 Unclear 
Marine oil or seafood 2.30 [0.45, 4.15] 5 (226) N/A 95.2 Yes 
DHA-rich egg 2.50 [1.69, 3.31] 1 (51) N/A N/A Unclear 
<300 mg DHA/day 1.24 [-0.19, 2.66] 3 (137) N/A 85.0 No 
300 to 1500 mg DHA/day 1.79 [0.60, 2.99] 3 (111) N/A 50.0 Yes 
1500 to 2500 mg DHA/day 3.34 [1.09, 5.59] 2 (93) N/A 89.0 Unclear 
>2500 mg DHA/day 3.80 [1.26, 6.34] 1 (20) N/A N/A Unclear 
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Figure 11: Response of total erythrocyte docosahexaenoic acid (DHA) to 
supplementation with DHA [%DHA/total fatty acid composition (weight/weight)] 
Specification of the groups as represented in the original articles: A, low fish oil group; B, combined 
data of middle fish oil and high fish oil groups; C, 2.5-g n–3 polyunsaturated fatty acid (PUFA) group; 
D, 5.1-g n–3 PUFA group; and E, 7.7-g n–3 PUFA group. 
 
4.3.3.8. Erythrocyte membrane phospholipid DHA 
Data on changes of erythrocyte membrane phospholipid DHA values on DHA 
supplementation were available in 6 RCTs. Primary analysis of the largest dose and 
longest duration showed a statistically significant increase in DHA values (MD: 0.97% 
DHA; 95% CI: 0.50, 1.43; 6 studies; 229 participants; I2 = 72%) with important 
heterogeneity (Table 16). Subgrouping suggested that erythrocyte phospholipid DHA 
is a good marker of DHA status in adults, females, those of moderate DHA status, 
and in those given single cell oils (Table 21). We included 7 substudies in the 
extended analysis of all doses. Although there were no data for the >2500 mg 
DHA/day dose category, we observed significant increases in the other 3 dose 
categories, although there were sufficient studies to declare the biomarker effective 
only in the 300–1500 mg DHA/day subgroup. Erythrocyte membrane phospholipid 
Study or Subgroup
1.4.1 < 300 mg DHA/day
Hoffman et al. 2004
Katan et al. 1997 A
Montgomery et al. 2003
Subtotal (95% CI)
Heterogeneity: Tau² = 1.26; Chi² = 13.32, df = 2 (P = 0.001); I² = 85%
Test for overall effect: Z = 1.71 (P = 0.09)
1.4.2 300 to 1500 mg DHA/day
Damsgaard et al. 2007
Katan et al. 1997 B
Palozza et al. 1996 C
Subtotal (95% CI)
Heterogeneity: Tau² = 0.57; Chi² = 4.00, df = 2 (P = 0.14); I² = 50%
Test for overall effect: Z = 2.95 (P = 0.003)
1.4.3 1500 to 2500 mg DHA/day
Dustan et al. 2004
Palozza et al. 1996 D
Subtotal (95% CI)
Heterogeneity: Tau² = 2.36; Chi² = 9.13, df = 1 (P = 0.003); I² = 89%
Test for overall effect: Z = 2.91 (P = 0.004)
1.4.4 >2500 mg DHA/day
Palozza et al. 1996 E
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.93 (P = 0.003)
Mean
5.5
4.6
3.1
7.7
4.8
7.2
11
6.9
8.6
SD
1.67
1.94
1.4
1.47
1.87
2.85
1.2
1.58
3.79
Total
25
15
29
69
24
29
10
63
36
10
46
10
10
Mean
3
4.4
2.4
5.4
4.4
4.8
6.6
4.8
4.8
SD
1.25
3
0.96
1.47
3
1.58
1.22
1.58
1.58
Total
26
14
28
68
24
14
10
48
37
10
47
10
10
Weight
36.8%
24.5%
38.7%
100.0%
49.5%
27.8%
22.7%
100.0%
54.0%
46.0%
100.0%
100.0%
100.0%
IV, Random, 95% CI
2.50 [1.69, 3.31]
0.20 [-1.65, 2.05]
0.70 [0.08, 1.32]
1.24 [-0.19, 2.66]
2.30 [1.47, 3.13]
0.40 [-1.31, 2.11]
2.40 [0.38, 4.42]
1.79 [0.60, 2.99]
4.40 [3.84, 4.96]
2.10 [0.72, 3.48]
3.34 [1.09, 5.59]
3.80 [1.26, 6.34]
3.80 [1.26, 6.34]
Supplementation Control Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Intervention lower Intervention higher
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DHA appears to be a good biomarker of DHA status. Although it may be an effective 
biomarker in adults, in children and adolescents, in pregnant or lactating women, and 
at most doses, this cannot be confirmed due to limited data. 
 
Table 21: Subgroup analysis of the results of the systematic review of data on 
changes in erythrocyte phospholipid docosahexaenoic acid (DHA) to 
supplementation with DHA, 
 
See details below Table 17. 
 
4.3.3.9. Total platelet lipid DHA 
Eight individual studies (4 RCTs and 4 B/A studies) reported changes of total platelet 
DHA values with DHA supplementation. The primary analysis showed statistically 
significant increases in response to supplementation (MD: 1.25% DHA; 95% CI: 0.87, 
1.64; 8 studies; 235 participants; I2 = 80%) with significant heterogeneity (Table 16). 
Although no data were available for the lowest DHA dose category, increases were 
seen at the other 3 doses (Table 22 and Figure 12). Subgrouping suggested that 
total platelet lipid DHA is a useful measure of DHA status for adults, males, mixed 
sex populations, and those at moderate DHA status. Total platelet lipid DHA may be 
a good biomarker of DHA status, but there was no apparent dose response, and the 
substantial heterogeneity could not be explained. 
  
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity
I
2
 
Biomarker 
useful? RCTs B/A 
 % of total fatty acid no. of studies (no. of participants) %  
All studies (primary outcome) 0.97 [0.50, 1.43] 6 (229) N/A 72.3 Yes 
Children and adolescents 0.50 [0.02, 0.98] 1 (49) N/A N/A Unclear 
Pregnancy and lactation 0.68 [0.22, 1.13] 2 (58) N/A 27.4 Unclear 
Adults 1.57 [0.47, 2.67] 3 (122) N/A 84.0 Yes 
Mixed 0.95 [-0.03, 1.92] 2 (128) N/A 77.1 Unclear 
Females 1.02 [0.38, 1.66] 4 (101) N/A 78.0 Yes 
Moderate status at baseline 0.73 [0.45, 1.02] 5 (213) N/A 30.9 Yes 
High status at baseline 2.80 [1.66, 3.94] 1 (16) N/A N/A Unclear 
Marine oil or seafood 1.59 [-0.66, 3.84] 2 (65) N/A 92.5 Unclear 
Single cell oil 0.91 [0.55, 1.27] 3 (130) N/A 28.6 Yes 
DHA-rich egg 0.38 [-0.27, 1.03] 1 (34) N/A N/A Unclear 
<300 mg DHA/day 0.53 [0.24, 0.81] 2 (78) N/A 0 Unclear 
300 to 1500 mg DHA/day 0.76 [0.53, 0.99] 3 (115) N/A 0 Yes 
1500 to 2500 mg DHA/day 2.09 [0.82, 3.35] 2 (95) N/A 70.1 Unclear 
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Table 22: Subgroup analysis of the results of the systematic review of data on 
changes in total platelet docosahexaenoic acid (DHA) to supplementation with DHA 
 
See details below Table 17. 
 
4.3.3.10. Peripheral blood mononuclear cell phospholipid DHA 
The response of peripheral blood mononuclear cell phospholipid DHA values to DHA 
supplementation was reported in 3 RCTs. There was no statistically significant effect 
of supplementation with DHA (MD: 0.70% DHA; 95% CI: -0.66, 2.06; 3 studies; 94 
participants; I2 = 94%) (Table 16). Peripheral blood mononuclear cell phospholipid 
DHA does not appear to be a good biomarker of DHA status. 
 
4.3.3.11. Other potential biomarkers 
One or 2 studies were found to include data on young erythrocyte ghost DHA, old 
erythrocyte ghost DHA, granulocyte DHA, neutrophil DHA, neutrophil phospholipid 
DHA, peripheral blood mononuclear cell total lipid DHA, low-density lipoprotein DHA, 
and high-density lipoprotein phospholipid DHA. There were insufficient data to 
assess whether these potential biomarkers of DHA status are effective. 
  
Analysis 
Pooled effect size 
MD (95% CI)  
Study design 
Heterogeneity
I
2
 
Biomarker 
useful? RCTs B/A 
 % of total fatty acid no. of studies (no. of participants) %  
All studies (primary outcome) 1.25 [0.87, 1.64] 4 (181) 4 (54) 79.9 Yes 
Adults 1.06 [0.69, 1.44] 4 (181) 2 (25) 72.8 Yes 
Low income and immigrants 1.70 [0.92, 2.48] N/A 2 (29) 75.1 Unclear 
Males 1.40 [0.70, 2.11] 1 (50) 2 (29) 86.3 Yes 
Mixed 1.37, [0.63, 2.11] 3 (131) N/A 88.8 Yes 
Females 0.73 [0.03, 1.42] N/A 2 (25) 0 Unclear 
Low status at baseline 2.80 [1.80, 3.80] 1 (21) N/A N/A Unclear 
Moderate status at baseline 0.89 [0.70, 1.07] 3 (160) 2 (25) 13.1 Yes 
High status at baseline 1.70 [0.92, 2.48] N/A 2 (29) 75.1 Unclear 
Marine oil or seafood 1.25 [0.87, 1.64] 4 (181) 4 (54) 79.9 Yes 
300 to 1500 mg DHA/day 0.94 [0.53, 1.35] 3 (228) 4 (54) 83.7 Yes 
1500 to 2500 mg DHA/day 0.70 [0.46, 0.94] 1 (105) N/A N/A Unclear 
>2500 mg DHA/day 1.91 [0.32, 3.51] 2 (61) N/A 89.1 Unclear 
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Figure 12: Response of total platelet docosahexaenoic acid (DHA) to 
supplementation with DHA [%DHA/total fatty acid composition (weight/weight)] 
Specification of the groups as represented in the original articles: A, high n–6 group; B, moderate n–6 
group; C, 2.0-g n–3 polyunsaturated fatty acid (PUFA) group; D, 6.6-g n–3 PUFA group; E, capsule 
group; F, food group; G, combined data of cod liver oil and seal oil/cod liver oil groups; and H, 
combined data of refined whale oil, crude whale oil, and olive oil/cod liver oil groups. 
 
 
4.4. Discussion 
We included 41 studies (34 RCTs and 7 B/A studies) reporting on 18 different 
potential biomarkers of n–3 LCPUFA status in this systematic review. There were 
sufficient data to state that plasma DHA, plasma phospholipid DHA, plasma 
triacylglycerol DHA, plasma cholesteryl ester DHA, plasma nonesterified DHA, 
erythrocyte DHA, erythrocyte phospholipid DHA, and platelet DHA were all effective 
biomarkers, peripheral blood mononuclear cell phospholipid DHA was an ineffective 
biomarker of DHA status and that plasma phospholipid EPA was an effective marker 
of EPA status. 
 
Study or Subgroup
1.5.1 < 300 mg DHA/day
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
1.5.2 300 to 1500 mg DHA/day
Brady et al. 2004 A
Brady et al. 2004 B
Christensen et al. 1999 C
Dyerberg et al. 2004
Vognild et al. 1998 H
Wallace et al. 2000 E
Wallace et al. 2000 F
Subtotal (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 36.72, df = 6 (P < 0.00001); I² = 84%
Test for overall effect: Z = 4.48 (P < 0.00001)
1.5.3 1500 to 2500 mg DHA/day
Vognild et al. 1998 G
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 5.74 (P < 0.00001)
1.5.4 >2500 mg DHA/day
Christensen et al. 1999 D
Park & Harris 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 1.18; Chi² = 9.16, df = 1 (P = 0.002); I² = 89%
Test for overall effect: Z = 2.36 (P = 0.02)
Mean
4.9
4.4
2.81
3.1
2.67
2.7
2.3
2.9
3.57
4.1
SD
0.75
0.77
0.4
0.49
0.84
2.08
1.08
0.58
0.5
1.58
Total
0
14
15
20
24
102
12
13
200
69
69
20
10
30
Mean
2.8
3.1
2.4
2.2
2.2
1.9
1.6
2.2
2.4
1.3
SD
0.75
0.77
0.6
0.51
0.6
1.04
1.05
0.6
0.6
0.33
Total
0
14
15
20
26
36
12
13
136
36
36
20
11
31
Weight
14.4%
14.5%
17.5%
18.0%
18.2%
6.5%
11.0%
100.0%
100.0%
100.0%
54.3%
45.7%
100.0%
IV, Random, 95% CI
Not estimable
2.10 [1.54, 2.66]
1.30 [0.75, 1.85]
0.41 [0.09, 0.73]
0.90 [0.62, 1.18]
0.47 [0.22, 0.72]
0.80 [-0.52, 2.12]
0.70 [-0.12, 1.52]
0.94 [0.53, 1.35]
0.70 [0.46, 0.94]
0.70 [0.46, 0.94]
1.17 [0.83, 1.51]
2.80 [1.80, 3.80]
1.91 [0.32, 3.51]
Supplementation Control Mean Difference Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Intervention lower Intervention higher
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For most of these biomarkers, however, only limited data were available for subgroup 
analysis. In contrast, we were able to evaluate the effect of n–3 LCPUFA 
supplementation on the fatty acid composition of plasma phospholipids on the basis 
of a considerable number of supplementation substudies. This finding is consistent 
with previous reports on the comparison of the incorporation of DHA and EPA into 
plasma phospholipids (Nordøy et al. 1991, Zuijdgeest-van Leeuwen et al. 1999) and 
supports the concept of using the enhancement of EPA values as an effective 
indicator of compliance in studies supplementing n–3 LCPUFAs.  
There are some clear limitations with this review. First, the number of studies 
reporting data on different potential biomarkers was >6 for only 3 outcomes (plasma 
phospholipid DHA, plasma phospholipid EPA, and platelet DHA). This limited our 
ability to explore the reasons for heterogeneity seen in the main analyses and also 
limited our ability to assess for which population subgroups and types of intervention 
the biomarkers are effective. For instance, EPA and DHA in erythrocyte membrane 
lipids were found closely correlated to those measured in cardiac biopsy samples 
(Harris et al. 2004) and were suggested as the most reliable biomarkers of n-3 
LCPUFA status (Harris 2007). However, until now, only limited data have been 
published on the effect of DHA supplementation on erythrocyte membrane lipids, 
thereby limiting evaluation in the present review. Second, we were able to focus on 
the effect of supplementing DHA only, whereas n-3 LCPUFA supplementation usually 
consists of a complex mixture of n-3 LCPUFAs that may interconvert with each other 
(Arterburn et al. 2006). Similarly, different food matrices can result in differences in 
absorption of nominally equal amounts of n-3 LCPUFAs. None of these factors could 
be reliably evaluated in the present review. Third, the dose-response curve of the 
incorporation of DHA (or any other fatty acid) may differ between compartments 
(Brown et al. 1991; Tremoli et al. 1995); hence, it may be assumed, with good 
reason, that the uniform duration and dose categories used in this review may have 
differently influenced the evaluation of the biomarkers. Additionally, we assessed the 
risk of bias to be low in only 5 included RCTs, limiting our ability to claim 
effectiveness. 
Despite these limitations, the data generated in the present systematic review may 
contribute to a better understanding of the role of biomarkers in evaluating n-3 
LCPUFA status in nutritional interventions. Although several clinical studies have 
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investigated the response of various biomarkers to modified n-3 fatty acid intake 
(Silverman et al. 1991, Nordøy et al. 1991; Zuijdgeest-van Leuwen et al. 1999; Brown 
et al. 1991; Tremoli et al. 1995; Prisco et al. 1996; Cao et al. 2006) and important 
theoretical considerations have also been published (Harris et al. 2004; Fokkema et 
al. 2002; Harris et al. 2006), we are unaware of any other systematic collection and 
evaluation of data available in the literature.  
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5. New findings of the thesis 
 
 
Plasma zinc concentration responded in a dose-dependent manner to dietary 
manipulation in adults, women, men, pregnant and lactating women, the elderly, and 
those at low and moderate baseline zinc status. Urinary zinc excretion responded to 
zinc status overall and in all subgroups for which there were sufficient data. Hair zinc 
concentration also responded, but there were insufficient studies for subgroup 
analysis. These results indicate that in healthy individuals, plasma, urinary and hair 
zinc concentrations are reliable biomarkers of zinc status. Platelet, 
polymorphonuclear cell, mononuclear cell, and erythrocyte zinc concentration and 
alkaline phosphatase activity did not appear to be effective biomarkers of zinc status. 
 
 
There were sufficient data to determine that plasma DHA, plasma phospholipid DHA, 
plasma triacylglycerol DHA, plasma cholesteryl ester DHA, plasma nonesterified 
DHA, erythrocyte DHA, erythrocyte phospholipid DHA, and platelet DHA were all 
effective biomarkers of DHA status, whereas peripheral blood mononuclear cell 
phospholipid DHA does not appear to be a good biomarker of DHA status and that 
plasma phospholipid EPA was an effective marker of EPA status. Plasma 
phospholipid DHA was the most frequently investigated biomarker; it appears to be a 
good marker of DHA status in adult men and women irrespective of DHA baseline 
status or supplementation dose, but ineffective marker in pregnancy and lactation; its 
usefulness in other population subgroups is unclear. 
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6. Practical applications 
 
 
At the present time, plasma zinc concentration is the only biomarker of status that 
can be used to measure zinc status in individuals with either a low or a high supply of 
dietary zinc, but with many limitations and constraints. Urinary zinc excretion and hair 
zinc can provide useful information on zinc status in zinc-supplemented individuals, 
but whether these reflect zinc status in depleted individuals is not certain. It is clear 
that there is an urgent need to develop new biomarkers of zinc status. 
 
 
Data presented in this thesis may be useful in designing novel studies on n-3 
LCPUFA supplementation, especially those aimed at answering the question as to 
which biomarker might be sensitive enough to detect changes of a given dose of n-3 
LCPUFA supplementation in a given clinical setting. There appears to be a range of 
useful biomarkers of DHA status in humans, but further research is needed to 
characterize which work best in particular population subgroups. 
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